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Epilepsy is a debilitating neurological disorder characterized by recurrent 
spontaneous seizures. While seizures themselves adversely affect physiological 
function for short time periods relative to normal brain states, their cumulative impact 
can significantly decrease patient quality of life in myriad ways. For many, anti-epileptic 
drugs are effective first-line therapies. One third of all patients do not respond to 
chemical intervention, however, and require invasive resective surgery to remove 
epileptic tissue. While this is still the most effective last-line treatment, many patients 
with ‘refractory’ epilepsy still experience seizures afterward, while some are not even 
surgical candidates. Thus, a significant portion of patients lack further recourse to 
manage their seizures – which additionally impacts their quality of life.  
High-frequency oscillations (HFOs) are a recently discovered electrical biomarker 
with significant clinical potential in refractory human epilepsy. As a spatial biomarker, 
HFOs occur more frequently in epileptic tissue, and surgical removal of areas with high 
HFO rates can result in improved outcomes. There is also limited preliminary evidence 
that HFOs change prior to seizures, though it is currently unknown if HFOs function 
as temporal biomarkers of epilepsy and imminent seizure onset. No such temporal 
biomarker has ever been identified, though if it were to exist, it could be exploited in 
online seizure prediction algorithms. If these algorithms were clinically implemented in 
implantable neuromodulatory devices, improvements to quality of life for refractory 
 
 x 
epilepsy patients might be possible. Thus, the overall aim of this work is to investigate 
HFOs as potential temporal biomarkers of seizures and epilepsy, and further to 
determine whether their time-varying properties can be exploited in seizure prediction.  
In the first study we explore population-level evidence for the existence of this 
temporal effect in a large clinical cohort with refractory epilepsy. Using sophisticated 
automated HFO detection and big-data processing techniques, a continuous measure 
of HFO rates was developed to explore gradual changes in HFO rates prior to seizures, 
which were analyzed in aggregate to assess their stereotypical response. These 
methods resulted in the identification of a subset of patients in whom HFOs from 
epileptic tissue gradually increased before seizures.   
In the second study, we use machine learning techniques to investigate temporal 
changes in HFO rates within individuals, and to assess their potential usefulness in 
patient-specific seizure prediction. Here, we identified a subset of patients whose 
predictive models sufficiently differentiated the preictal (before seizure) state better than 
random chance.  
In the third study, we extend our prediction framework to include the signal 
properties of HFOs. We explore their ability to improve the identification of preictal 
periods, and additionally translate their predictive models into a proof-of-concept seizure 
warning system. For some patients, positive results from this demonstration show that 
seizure prediction using HFOs could be possible. 
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These studies overall provide convincing evidence that HFOs can change in 
measurable ways prior to seizure start. While this effect was not significant in some 
individuals, for many it enabled seizures to be predicted above random chance. Due to 
data limitations in overall recording duration and number of seizures captured, these 
findings require further validation with much larger high-density intracranial EEG 
datasets. Still, they provide a preliminary framework for the eventual use of HFOs in 
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Chapter I: Introduction 
During the transition toward sleep each night, the physiological rhythms of the 
human body gradually slow until the body is mostly motionless. The brain does not 
follow this trend, however. After wakefulness departs, neural activity in the brain is 
renewed and even intensifies: this is evident first in the waves of high amplitude 
synchronous activity of slow wave sleep, and then in the dramatic flourish of dissociated 
activity known as rapid eye movement sleep (REM sleep) [1]. To a parent observing a 
child dreaming under REM sleep, this veritable symphony in the brain might not be 
physically evident, except perhaps for the light flicker of the eyes beneath their lids. The 
arrival of such a moment for a relieved parent, however, is often the result of a practiced 
nightly routine that might involve pajamas and story books. Indeed for anyone, this 
nightly lapse in consciousness – and the act of sleep in general – requires some 
amount of forethought and preparation to ensure the body’s safety while the mind drifts 
between dream states, blissfully unaware.  
At first glance, it might seem that the serene sleep of a child would have nothing in 
common with the pronounced convulsions of someone experiencing an epileptic 
seizure. If the two are compared in a more abstract sense, however, there are intriguing 
parallels between the phenomena of sleep and seizures. Both sleep and seizures are 
characterized by significant transitions of bodily state that exert powerful control over 
cardiovascular and musculoskeletal functioning [2], [3]. In the brain, these state 
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changes also result in distinct patterns of neural activity that display periods of 
increased synchrony [4]. Crucially, sleep and seizures are both capable of significantly 
altering individual awareness and level of consciousness [4]. Despite the apparent 
similarities between sleep and seizures, however, they have diametrically opposed 
effects on the body: sleep generally rebuilds and restores vital physiological processes, 
but seizures instead disrupt them and even damage them over many occurrences. 
Spontaneous seizures that occur repeatedly – which are a defining characteristic of the 
disease of epilepsy – are associated with increased risk of injury and even death [5]. 
In addition to negative physiological effects, the unseen psychosocial costs of 
recurrent seizures are significant [6]. Seizures strike suddenly and without warning, 
which can leave unconscious or recovering individuals vulnerable to their surroundings, 
and at the mercy of passersby to deliver aid. This is in stark contrast to sleep and the 
nightly bedtime rituals of parent and child described above. Thus, seizures represent an 
unplanned and pathological gap in consciousness that cannot be sufficiently prepared 
for. For those with recurrent seizures and the disease of epilepsy, this looming and 
seemingly random threat is a significant detractor to overall wellness and quality of life 
[7]. Epilepsy does this in a variety of ways, from the disease’s persistent social stigma 
[8], to its negative impact on individual financial health and education possibility [9], and 
by something as simple as not being able to drive a car [7]. Psychosocial effects of 
epilepsy also extend significantly to family members, caretakers, and relatives [10]. 
Still, the chief complaint of those with uncontrolled epilepsy is the random nature of 
seizures [11]. If it were hypothetically possible to know the exact timing of an individual’s 
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seizures in any given day, life’s activities could be planned or rerouted with more ease, 
and more importantly, patient safety could be addressed by preparing for the seizures 
themselves. While seizures likely do not occur in this rigidly deterministic fashion [12], it 
is likely that even limited foresight of future seizure timing could significantly improve 
patient quality of life. This idea is at the center of this work’s ultimate end goal: to 
eventually address patient quality of life by investigating and developing a novel 
biomarker of seizure timing in the context of seizure prediction and probabilistic 
forecasting. 
Background and motivation 
Seizures: A fundamental property of neuronal networks is their ability to exhibit 
seizure-like activity [13]; this is found in simple organisms like fruit flies [14] and 
zebrafish [15], and it is also conserved in more complex and developed organisms like 
mammals [13]. Shown in the intracranial EEG waveforms in Figure 1 below, a seizure 
itself is the paroxysmal firing of large neuronal populations in synchrony [3]. Seizures 
manifest physically in myriad ways [16], and their severity ranges from brief periods of 
impaired awareness to complete loss of consciousness with accompanying rhythmic 
convulsions of limbs and body. This variety is in part because a seizure is not in and of 
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itself a disease, but rather an epiphenomenon of underlying neuronal pathology [3]. 
Approximately 1 in 10 people will have at least one unprovoked seizure in their lifetime 
[17], [18], and the probability of having additional seizures increases every time one is 
experienced [19].  
Epilepsy: The disease of epilepsy is defined as the recurrence of spontaneous 
seizures, and it is one of the most prevalent neurological disorders in the world, 
affecting 60 million total [3], [17], [18]. It is also a highly heterogeneous disease with 
many different types of syndromes, each of which can result from a variety of etiologies 
[20], [21]. After diagnosis –  which is conducted with a thorough review of patient history 
and commonly includes scalp electroencephalogram monitoring (EEG) to identify the 
presence of interictal epileptic discharges (IEDs) – affected patients are typically put on 
a regimen of anti-epileptic drugs, which generally function by calming aberrant 
electrophysiological processes in the brain [22].  
Treatments for refractory epilepsy: Approximately one third of individuals with 
epilepsy do not respond to anti-epileptic drugs (AEDs), however [23]. These patients 
FIGURE 1: Example seizure waveform. This seizure originated in data recorded from patient UMHS-0026. 
Overall the seizure lasts approximately 30 seconds. It begins with a large spike and DC shift in many 
channels; subsequently it evolves and increases in amplitude until reaching a maximum at seizure offset, 
where several bursts of spikes follow. 
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with ‘refractory epilepsy’ typically move through a variety of AED combinations before 
their treating clinicians arrive at the conclusion that other more invasive treatments are 
necessary. There are two last-line therapies available in this regard: 1) resective 
surgery, which removes epileptic tissue thought to be generating seizures, or 2) 
implantable neuromodulatory devices, which deliver electrical impulses either in 
response to certain electrical patterns (referred to as closed-loop or responsive 
stimulation [24]), or in a continuous fashion using a predefined stimulus (open-loop 
stimulation). 
Unmet clinical need in refractory epilepsy: Resective surgery remains the gold-
standard treatment for refractory epilepsy, as the effectiveness of devices still falls 
below [25]–[28]. After one year, however, only 60% of resected patients are seizure-free 
[29]. Further, many patients with refractory epilepsy are not surgical candidates either 
because their seizures originate from multiple foci, or because the seizure-generating 
tissue overlaps with important and vital brain areas related to speech, movement, or 
sight. Thus, there is significant unmet clinical need in the sizable portion of refractory 
epilepsy patients still experiencing seizures.  
 High-frequency oscillations: High-frequency oscillations (HFOs) are a more 
recently discovered electrical biomarker of epilepsy that have begun to address this 
clinical need. HFOs are brief ( < 50 ms) and somewhat rare neuronal events that occur 
in frequencies from 80 - 500 Hz [30]; there is also evidence that they occur in higher 
frequencies as well [31]. Though they can be associated with normal physiological 
processes involving memory and vision [32], [33], brain tissue with comparatively high 
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HFO rates is associated with epileptogenicity [21], [34], [35]. Importantly, surgical 
removal of high HFO tissue can result in better clinical outcomes and increased seizure 
freedom [36]–[40].  
Using microwire electrodes, pathological HFOs were originally discovered 
approximately 20 years ago in humans and in animal models of mesial temporal lobe 
epilepsy (MTLE) [41]. It was quickly confirmed that HFOs are recordable with standard 
intracranial grid, and depth electrodes [42]; recently, they have also been identified with 
standard scalp EEG as well [43]. In the literature, HFOs are commonly subdivided into 
‘ripples’ (80 - 200Hz) and ‘fast ripples’ (250 - 500 Hz). Initially it was thought that fast 
ripples had more of a pathological association [44], but recent evidence questions this 
assumption [45]–[47] To date there are no reliable methods to separate physiological 
and pathological HFOs [48]. The exact biological mechanism for HFO generation is 
unknown, but both epileptic ripples and fast ripples are currently thought to be the result 
of synchronous firing by principal pyramidal cells [49]. 
Recording HFOs: There have been significant advances in the technology used to 
record, and process HFOs since they were first discovered [42], [50]. Initially, clinical 
EEG systems could not adequately address the difficulties involved with recording 
HFOs. In order to accurately discern an HFO waveform, a sampling rate of at least 2 
kHz is required [42], [50], but they are more easily identified as sampling rate increases 
[51]; until somewhat recently, most clinical systems were limited to sampling 
frequencies of 256 Hz. HFOs are also low amplitude events compared to their 
surrounding backgrounds; this signal-to-noise ratio was also a challenge that more 
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modern amplifiers had to overcome. But given the increasing demand for HFO 
recordings, clinical EEG manufacturers have responded with the development of 
advanced amplifiers that have low noise floors and high-sampling frequencies. [34] 
Automated identification of HFOs: HFOs were originally identified manually in 
short 10-minute clips of data by visual inspection of raw and filtered waveforms [52], 
[53]. As recordings grew in duration and number, however, it was clear that this labor-
intensive method was prohibitive of more advanced analyses with more patients. Using 
visual inspection as validation, a number of automated HFO detectors were developed 
(see [54] for a review) that could parse a huge amount of intracranial data in a small 
fraction of the amount of time it would take a human reviewer. These detectors have 
allowed the proliferation of numerous HFO studies in the literature today; many of these 
have contributed to the generally accepted understanding that HFOs are spatial 
biomarkers of epileptic tissue.  
Thesis motivation – HFOs. While the spatial aspect of HFOs somewhat 
predominates the literature, other facets and research questions have gone unexplored 
that could still show significant clinical potential. Notably, there are few studies that have 
explored how HFOs change over time, and fewer still that have investigated such 
changes prior to seizure onset. The only two studies in this regard [55], [56] were limited 
by small patient cohorts and few seizures per patient. Still, both identified significant 
changes in preictal (meaning prior to seizure) HFOs in some patients. However, they 
came to opposing conclusions as to whether these changes were stereotyped, and 
additionally whether such preictal changes were truly different from changes in HFOs 
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observed during interictal periods (meaning between seizures). Thus, it is largely 
unknown if HFOs are temporal biomarkers of seizure onset and whether they can be 
used in seizure prediction or forecasting. This open question is the primary motivation 
for the novel investigation of HFOs presented in this thesis.  
Seizure prediction: There is tremendous clinical potential in the pursuit of accurate 
seizure prediction. As such, the prediction of epileptic seizures has been the focus of 
much research over the past two decades. The first prediction studies used large 
numbers of EEG-derived features in small data sets to prove that prediction was 
possible [57]. These studies lacked statistical validation that their prediction algorithms 
performed better than a random chance predictor, however. After this misstep, a set of 
statistical requirements and associated methods were adopted by the field to add rigor 
and consistency to future prediction studies [58]–[60]. These methods include seizure 
time surrogates, where labels on seizure and non-seizure periods are randomly 
permuted [61]; comparisons using a random Poisson predictor [62], and the AUC 
metric, which has since been used in many studies [63]–[65] and is used throughout this 
thesis.  
Neurovista and prospective prediction: In 2013, the defining achievement in 
seizure prediction came from the development of an implantable intracranial monitoring 
device, called the ‘Neurovista’ device [66]. It resulted in chronic recordings of high-
quality ambulatory iEEG for 13 patients; in some patients these recordings spanned 
months and close to years. In addition to recording intracranial data, the device also 
functioned as a seizure forecasting system, and would alert the wearer to their current 
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seizure risk. This aspect of the device used signal features derived from incoming 
intracranial EEG data as the input to a true prospective prediction algorithm – which, to 
this day, stands as the only such instance of its kind. The iEEG data acquired during 
this study has since been used in numerous prediction studies [64], [65], [67]–[71]; 
some of those algorithms evaluated seizure risk retrospectively by evaluating all data at 
once, and others used pseudo-prospective approaches to evaluate seizure risk moving 
forward continuously in time, mimicking the original Neurovista method.  
Thesis motivation – seizure prediction. Along with our evolving understanding of 
epilepsy and seizures, the knowledge gained from early and more recent seizure 
prediction studies is shaping the field’s future. A recent review [12] of seizure prediction 
written by seminal experts in the field detailed a number of strategies and research 
goals to be pursued in future work; these included the following: 1) further development 
of pre-seizure electrical biomarkers, 2) the pursuit of patient- and possibly even seizure-
specific prediction algorithms, and 3) the reformulation of seizure prediction into a 
probabilistic rather than deterministic framework. By exploring HFOs in the context of 
seizure prediction and probabilistic forecasting, the work of this thesis is directly 
motivated by all three items above: given the previously described variability of 
individual outcomes for HFO studies involving temporal changes in the preictal period 
[55], [56], it is possible that HFOs are a patient-specific biomarker of seizure onset, 
capable of use in seizure prediction. Additionally, recent evidence has shown that HFOs 
occurring at the beginning of a seizure can differentiate between two different seizure 
types [72], a finding which is relevant to seizure-specific prediction using HFOs.  
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Thesis aims and organization 
With the ultimate goal of improving quality of life for patients with refractory epilepsy, 
this thesis addresses two general aims: 1) to evaluate HFOs as a temporal biomarker of 
seizure onset and epilepsy, and 2) to assess the relevance of these findings to seizure 
prediction. These aims are addressed across the findings of three independent studies.  
Using a big-data framework that was developed in concert with state-of-the-art HFO 
identification and processing methods, the first study in Chapter II investigates temporal 
properties of preictal HFO rates at the population level to identify the existence of this 
effect, and its potential prevalence within a large clinical cohort. We develop a novel 
continuous measure of HFO rate (cHFO), and use this to analyze preictal and interictal 
time periods together to identify stereotypical patterns – first in individuals, then 
compared at the population level – that differentiate pre-seizure data.    
The second study in Chapter III addresses HFOs as a potential patient-specific 
biomarker of imminent seizure onset. We characterize fluctuations in the distribution of 
HFO rates through time across several sliding windows of different duration. These data 
are used to train logistic regression models – a framework chosen for its probabilistic 
output – to identify differences in preictal versus interictal HFOs. The predictive 
performance of these models with unseen held-out data is cross-validated and then 
assessed with the AUC metric, which affords an overall idea of how well the predictive 
classifiers can differentiate preictal from interictal periods.  
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The third study in Chapter IV is a significant expansion of the techniques and 
analyses presented in Chapter III. It extends the data used for prediction and 
forecasting to include information about HFO signal features. The predictive 
performance of these models is then compared with the performance of models in 
Chapter III to assess their increased utility in seizure prediction. Finally, this study 
demonstrates the practical potential of HFOs in seizure prediction and forecasting by 
providing an implementation of a seizure-warning system. This study is meant to show 
that HFOs could help forecast oncoming seizures, and motivates the use of high 
resolution EEG in future devices.  
Overall this thesis presents several significant contributions to HFO research and 
seizure prediction in epilepsy. The techniques and methodologies for HFO identification 
and processing used in all three studies represent significant advances in the use of 
HFOs in a big data framework – particularly for HFO data around seizures, whose 
accuracy had not sufficiently been addressed. The use of this framework with the HFO 
data of a large clinical cohort provides further validation of these results. The use of 
HFOs in seizure prediction is a novel idea that, prior to this thesis, has not been 
investigated in the literature. It is hoped that these findings can serve as preliminary 
waypoints to further research on the temporal aspects of HFOs, especially in the 
context of seizure prediction.
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Chapter II: Preictal Variability of High-Frequency Oscillation Rates in Refractory 
Epilepsy  
J. M. Scott, S. Ren, S. V. Gliske, and W. C. Stacey, “Preictal variability of high-frequency 
oscillation rates in refractory epilepsy,” Epilepsia, 2020. 
Abstract 
Objective: High-frequency oscillations (HFOs) have shown promising utility in the 
spatial localization of the seizure onset zone for patients with focal refractory epilepsy. 
Comparatively few studies have addressed potential temporal variations in HFOs, or 
their role in the preictal period. Here, we introduce a novel evaluation of the 
instantaneous HFO rate through interictal and peri-ictal epochs to assess their 
usefulness in identifying imminent seizure onset. Methods: Utilizing an automated HFO 
detector, we analyzed intracranial electroencephalographic data from 30 patients with 
refractory epilepsy undergoing long-term presurgical evaluation. We evaluated HFO 
rates both as a 30-minute average and as a continuous function of time and used 
nonparametric statistical methods to compare individual and population-level 
differences in rate during peri-ictal and interictal periods. Results: Mean HFO rate was 
significantly higher for all epochs in seizure onset zone channels versus other channels. 
Across the 30 patients of our cohort, we found no statistically significant differences in 
mean HFO rate during preictal and interictal epochs. For continuous HFO rates in 
seizure onset zone channels, however, we found significant population-wide increases 
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in preictal trends relative to interictal periods. Using a data-driven analysis, we identified 
a subset of 11 patients in whom either preictal HFO rates or their continuous trends 
were significantly increased relative to those of interictal baseline and the rest of the 
population. Significance: These results corroborate existing findings that HFO rates 
within epileptic tissue are higher during interictal periods. We show this finding is also 
present in preictal, ictal, and postictal data, and identify a novel biomarker of preictal 
state: an upward trend in HFO rate leading into seizures in some patients. Overall, our 
findings provide preliminary evidence that HFOs can function as a temporal biomarker 
of seizure onset.  
Introduction 
High-frequency oscillations (HFOs) have shown promise in clinical epilepsy 
research as a biomarker of epileptic tissue. Defined as short bursts of neural activity > 
80 Hz, HFOs occur more frequently in epileptic tissue [30], [35] Numerous studies have 
shown that HFOs accurately delineate the seizure onset zone and potentially improve 
surgical outcomes [36]–[40]. Although most HFO studies concentrate on localization of 
abnormal channels, there is interest in characterizing other aspects of HFOs and 
epilepsy [43]. As high-frequency activity has been shown to increase prior to seizure 
onset both clinically and in experimental models, [73]–[75] some have also 
hypothesized a link between HFOs, the mechanisms of ictogenesis, and preictal brain 
states [49], [72], [74]–[80]. 
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The existence of a preictal state is still unproven, but growing evidence suggests it 
is measurable in many patients [58], [81], [82]. One notable study found differences in 
preictal electroencephalogram (EEG) occurring even hours before seizure onset [82]. 
However, very few studies address HFOs in the preictal period. Early work with small 
cohorts showed that preictal HFOs have subtle changes in the preictal period, such as 
spectral and rate changes [55] or alterations in HFO features [56]. Newer hardware and 
software now make HFO research much more robust, allowing high-quality, larger 
datasets [56], [77], [83]–[86]; the role of HFOs as a preictal biomarker can now be 
answered with much higher rigor. To our knowledge, there is no study of peri-ictal HFO 
rates using modern equipment and algorithms to acquire a robust sample size. This has 
halted further progress toward our understanding of the temporal evolution of HFOs and 
their relationship to mechanisms of seizure generation and termination. Furthermore, it 
has prevented the adoption of HFOs as a temporal biomarker.  
We designed this study to directly address these deficits. Here, we analyze >11 
million automatically detected HFOs from the entire intracranial EEG record of 30 
patients. We adapt the analysis to generate the first robust comparison of peri- and 
interictal HFO rates. We find a subset of patients in whom HFO rates change up to 30 
minutes prior to seizures, which we suggest can be used as a temporal biomarker of 
impending seizure onset in future seizure prediction applications.  
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Methods 
Patient population: Data were acquired from all consecutive patients at the 
University of Michigan who had intracranial EEG (iEEG) monitoring for refractory 
epilepsy with at least 4096 Hz sampling rate from 2016 to 2018. For inclusion in the 
study, patients had to have a total recorded time of at least 24 hours, during which at 
least 1 seizure occurred. Additionally, we required sufficient metadata regarding 
channel mappings, seizure times, and other clinical data. This produced a total of 30 
patients for the study. Electrodes implanted for monitoring included a mix of subdural 
grids, conventional depth electrodes, and stereo-EEG electrodes. Channels were 
labeled as “seizure onset zone,” and seizure onset/offset times were determined, 
according to the official clinical report of the treating epileptologist. Channels were 
labeled as lying within “resected volume” by consultation with the neurosurgeon and 
comparison of pre- and postoperative imaging (when available). Prior to data 
acquisition, full institutional review board approval was obtained, as well as written 
consent from patients to share their deidentified data. All EEG data were acquired with 
a Quantum amplifier (Natus Medical) with a sampling rate of 4096 Hz. Further summary 
of the patient population can be found in Table 1.  
Data processing and analysis: All data were analyzed using custom C++ and 
MATLAB (MathWorks) packages and scripts. As seen in Figure 2, our data analysis 
workflow consisted of three main components: automated HFO detection, indexing and 
windowing operations, and statistical analysis of mean and continuous HFO rates. 
These individual steps are described below. 
 
  16 
 
TABLE 1: Clinical data for first study. Abbreviations: M/F: male, female, L/R: left / right, T: temporal, P: parietal, F: frontal, Occ: occipital, 
DNET: dysembryoplastic neuroepithelial tumor, NF1: neurofibromatosis type 1 tumor, NR: not resected, CD: cortical dysplasia, MTS: 
medial temporal sclerosis, PVNH: periventricular nodular heterotopia, PMG: polymicrogyria, VNS: vagal nerve stimulator. 
(hemisphere, (#/min./channel)
region) total ECoG depth SOZ (hours) SOZ OUT SOZ OUT total used
UMHS-0019 59 F II R T Gliosis 106 106 0 2 168.8 400,123 1.99 0.17 156.2 161.6 5 1 X X
UMHS-0020 45 F II R T MTS 25 0 25 9 171.2 55,311 0.36 0.13 172.7 221.8 7 7
UMHS-0021 30 M II R T
Gliosis, PVNH, 
PMG
46 0 46 13 179.5 459,037 1.91 0.47 169.9 166.8 9 6
UMHS-0022 40 M I L T CD, MTS 38 0 38 3 160.8 72,486 1.38 0.06 190.0 182.7 8 5 X
UMHS-0023 29 M NR L T, P PVNH / Neuropace 69 41 28 29 164.3 354,931 0.83 0.34 157.0 166.4 20 9
UMHS-0024 31 M NR L, R T Neuropace 75 55 20 16 177.2 1,124,176 2.62 1.24 152.1 154.6 28 11
UMHS-0025 17 F II L T Gliosis 20 0 20 5 207.7 269,638 1.77 0.88 161.6 172.8 10 3 X
UMHS-0026 22 F NR R T PVNH 52 0 52 3 246.2 390,187 1.52 0.51 165.3 166.3 40 7 X X X
UMHS-0027 26 M NR L Diffuse VNS 91 81 10 3 205.2 1,212,921 2.98 2.19 148.3 154.0 97 8 X
UMHS-0028 14 F I R T Tumor: Glioma 53 47 6 5 79.7 198,968 2.39 0.37 154.3 159.2 7 4 X
UMHS-0029 48 M NR L T, Occ. Neuropace 91 91 0 22 226.3 819,880 0.61 0.72 159.3 168.1 14 7
UMHS-0030 5 M III L T MTS, Gliosis 100 100 0 2 146 378,824 1.01 0.56 152.3 169.0 33 12
UMHS-0031 13 M I L T
Gliosis, Tumor: 
NF1
99 99 0 6 180 371,855 0.75 0.24 150.4 159.4 9 6
UMHS-0032 41 F I R F CD 32 0 32 3 184.3 382,400 2.45 0.64 159.4 170.5 8 6 X X X
UMHS-0033 5 F II R Ins. CD, Gliosis 74 0 74 4 120.7 150,963 0.97 0.30 169.8 219.7 28 19
UMHS-0034 33 F I R F Gliosis 32 0 32 11 136.3 455,089 2.41 1.18 172.2 167.3 17 16
UMHS-0035 50 F I L T Gliosis 57 57 0 2 162.7 122,451 0.67 0.19 147.9 172.4 7 6
UMHS-0036 43 M NR L, R T CD / Neuropace 54 0 54 2 172.5 335,274 1.36 0.60 151.8 163.6 18 12
UMHS-0037 14 M I L F Tumor: DNET 50 0 50 - 219.7 229,207 - 0.30 -  157.3 34 22
UMHS-0038 28 M II L T MTS, Gliosis 61 61 0 - 178.7 746,718 - 1.16 -  156.5 7 2
UMHS-0039 47 M NR R P CD / Neuropace 90 0 90 10 155.2 233,050 0.99 0.22 160.6 184.0 19 7
UMHS-0040 14 F I L P CD, Gliosis 63 55 8 8 196.7 386,462 0.37 0.64 158.7 170.1 7 7 X
UMHS-0041 32 F I R F CD 71 0 71 9 176.5 73,589 0.30 0.04 166.7 191.0 36 3
UMHS-0043 28 M II R T Gliosis 86 0 86 9 182.2 279,124 0.75 0.33 170.9 226.8 46 5 X
UMHS-0044 45 F NR L T, P Neuropace 76 0 76 6 170.2 385,032 1.24 0.45 155.4 179.6 13 4
UMHS-0045 17 F NR L, R T Neuropace 94 0 94 15 331.5 645,420 0.76 0.24 167.3 185.8 6 6
UMHS-0046 23 F I L F CD 30 0 30 9 139.3 16,061 0.12 0.03 166.1 210.8 17 8
UMHS-0047 48 F II R T Gliosis 70 0 70 3 301.7 417,307 0.65 0.22 155.0 196.8 1 1 X
UMHS-0048 22 F NR L, R T Neuropace 86 0 86 8 141.8 271,327 2.29 0.25 164.6 178.0 23 3 X
UMHS-0049 53 F NR L, R T Neuropace 94 0 94 15 176.8 179,259 0.63 0.11 179.6 166.9 17 4
TOTALS / averages 1985 793 1192 232 5459.5 11,417,070 1.29 0.49 162.0 178.1 591 217 7 4 5
HFO                   
mean           
frequency
(median, Hz)
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Automatic HFO detection and electromyographic artifact removal: For 
automated HFO detection, we used a previously validated HFO detector [86]. Briefly 
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FIGURE 2: Schematic diagram showing overall data analysis workflow. A, Quality high-frequency 
oscillation (HFO) detections (quality HFOs [qHFOs]) and their respective interictal and peri-ictal windows 
of analysis are aligned in time to compute mean and continuous HFO rate. EMG, electromyographic. B, 
Analysis windows are created from patient metadata and excluded from further analysis if overlap occurs 
with a number of conditions that would bias results. C1, Remaining peri-ictal windows are further divided 
into preictal, ictal (which includes a 1-minute buffer on either side of the clinically marked seizure time), 
and postictal epochs. C2, Remaining interictal windows are defined as 30-minute epochs. D, Continuous 
HFO rate (cHFO) computed from a single seizure in an individual patient is shown for seizure onset zone 
channels (top row, SOZ) and nonepileptic channels (middle row, OUT). cHFO rates were computed from 
discrete HFO detections, shown as a raster plot of preictal detections (bottom row) and organized by 
channel index. This patient (UMHS-0040) was a member of the “slope responder” subset of patients and 
showed preictal increases in cHFO rate as onset approached. Here cHFO rate is defined as HFOs per 
minute per channel. Dotted lines indicate ±1 standard deviation; blue denotes preictal cHFO rate, and 
green denotes interictal cHFO rate for comparison. The peri-ictal window was truncated for display 
purposes at 40 minutes. E, Example HFO detections for the same patient in interictal, preictal, ictal, and 
postictal periods are visualized in time-frequency plots, each computed with the Morse wavelet.  
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Hz) data, then redact detections likely to be due to artifacts, leaving more specific 
“quality HFOs” (qHFOs). We also applied an additional, published artifact rejection 
method designed to redact activity associated with scalp muscle artifact, which can 
produce many false-positive detections in the lateral temporal lobes [85]. All HFOs 
discussed in this work were subjected to this full process.  
Adjusting HFO detector for peri-ictal periods: All resulting HFOs for a given 
patient were labeled as either interictal baseline or peri-ictal, which we defined to 
include the full period from 30 minutes prior to 30 minutes after a seizure. Interictal 
HFOs were indexed into a successive series of interictal windows whose individual 
duration was 30 minutes. Peri-ictal detections were further subdivided into three 
continuous epochs: preictal, ictal, and postictal. We defined the preictal and postictal 
epochs as beginning 30 minutes before and ending 30 minutes after the ictal epoch, 
respectively. The ictal epoch was defined by the clinical mark of beginning and end, as 
well as an additional 1-minute buffer before and after the seizure. This buffer was added 
to mitigate potential inconsistencies in clinically marked seizure times, which can vary 
between clinicians [87], [88]. A schematic showing the exact timing of these epochs is 
given in Figure 2C.  
Most automated HFO detectors are designed for interictal data, where the EEG 
baseline is assumed to be relatively stable over time; the HFO detection algorithm 
compares with the baseline EEG every 10 minutes, which is assumed to be interictal 
[52]. However, including peri-ictal data presents a new challenge, because a seizure 
changes the “baseline” significantly and disrupts the threshold for HFO detection. To 
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address these considerations, we used two simple modifications to our HFO detection 
process during peri-ictal periods.  
The first modification was designed to align the 10-minute windows correctly to 
ensure ictal data were not present in the preictal epochs. This did not change the 
method of HFO detection, merely the start and stop times for the preictal epochs. 
During peri-ictal periods, the baseline was referenced to the start of the seizure, that is, 
the HFO detector was started 31 minutes prior to each seizure onset, which includes 
the aforementioned 1-minute buffer. From this point, the detector ran in successive 10-
minute segments until reaching the end of the postictal epoch as we have defined it 
above. Aligning the qHFO detector in this manner ensured that ictal EEG activity did not 
contaminate the preictal baseline threshold used to identify HFOs. Note that if baseline 
also increased preictally, this would lead to fewer HFOs being detected during the 
preictal period. Thus, the results herein are a conservative estimate of preictal HFOs.  
Second, we fixed the “baseline” threshold used for ictal and postictal HFO detection 
to the value of the 10-minute preictal segment just prior to the ictal period. This ensured 
that ictal and postictal rates were scaled to preictal baseline, rather than ictal activity. 
This was necessary because ictal data typically have a much higher baseline root mean 
square value than the preictal portion that precedes it, and our understanding of 
“increased HFO rates,” as well as the automated detector, is based upon comparison 
with interictal baseline. This method ensured the ictal and postictal rates would be 
referenced to the preictal baseline, prior to any ictal activity.  
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Window exclusion and alignment: Because the peri-ictal and interictal data have 
different reference points, it is possible that the windows overlap with each other or with 
periods of unreliable data. To ensure data quality and no overlap, we excluded windows 
that could be unreliable (Figure 2B). Specifically, we redacted windows that had overlap 
with any of the following conditions: (1) any other window, (2) file start or stop times, (3) 
gaps in recorded data of 1 minute or more, and (4) known extraoperative mapping 
procedures or other similar periods of poor data quality. Windows meeting any of these 
conditions were labeled unusable and excluded from further analysis. After this 
procedure, there were 217 seizures available for processing in the 30 patients. 
Remaining windows were then sorted according to type (i.e., interictal baseline or peri-
ictal) and aligned in time, which allowed comparison of HFO times across all windows. 
Grouping these windows then allowed computation of average HFO rates as described 
below.  
Computing HFO rate: Our analysis utilized two different representations of HFO 
rate: mean HFO rate and continuous HFO (cHFO) rate. These values were computed 
across two groups of intracranial channels: seizure onset zone channels (hereafter 
abbreviated SOZ), and all channels that were outside of both the SOZ and the volume 
of resected tissue (RV), which we denote OUT. Note that there is usually a great deal of 
overlap between SOZ and RV, but RV often has many channels that were not in the 
SOZ, and may not contain all of the SOZ, depending upon clinical circumstances. Mean 
HFO rate was computed as the average over all usable windows and was defined as 
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the total number of HFOs divided by the product of the number of channels and total 
duration of the windows used.  
cHFO rate: The Nelson-Aalen hazard rate: A robust analysis of temporal 
characteristics of HFOs requires information on their rate as a function of time, rather 
than simply an average over long epochs. We estimated HFO rates as a continuous 
function of time (cHFO rates), with the nonparametric Nelson-Aalen hazard rate model, 
and smoothed its output with kernel methods [89]–[91]. In a general sense, the Nelson-
Aalen model gives the risk of an event's occurrence as a function of time, which is 
equivalent to its instantaneous rate [90]. This method has been used to quantify 
oscillatory activity during sleep [92] as well as the risk of seizures over time [93].  
Kernel smoothing methods can translate discrete events into continuous estimates 
of rate, but they require the selection of a bandwidth parameter, which generally 
controls how jagged or smooth the estimate appears. We fixed this parameter at 1 
minute for all patients, which prevented ictal HFOs from influencing preictal cHFO rates 
as the kernel window moved forward in time.  
We computed cHFO rates with the Nelson-Aalen model in the same general 
manner as mean HFO rates, with one exception. Instead of using all interictal windows 
in the Nelson-Aalen computation, we restricted their number to be equal to the number 
of usable peri-ictal windows, choosing them at random from all usable interictal 
windows. While this allowed us to characterize interictal cHFO rates with the same 
temporal scale as peri-ictal cHFO rates, it also meant that interictal cHFO rates were 
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only calculated from a portion of the available data. To mitigate this, we repeated the 
calculation 10 times with different random selections and report the average of all 10 as 
the final estimate.  
Final analysis and statistical tests:	After determining mean and continuous HFO 
rates for all patients, we compared interictal and peri-ictal rates across all patients. We 
assessed patient-wise differences in mean HFO rate across channel groups (SOZ, 
OUT) and epochs (interictal, preictal) with the Wilcoxon signed rank test, using the 
appropriate Bonferroni correction. We also used the Kolmogorov-Smirnov test to 
compare differences in the population distributions of mean HFO rate across channel 
groups.  
The cHFO rate is a continuous variable that estimates the instantaneous rate at 
every point in time. We first analyzed these results visually and noticed two clear groups 
of patients: (1) most patients had essentially stable cHFO rates preictally, which were 
similar to the interictal values; and (2) some patients had preictal cHFO rates that were 
larger than the interictal values and appeared to increase leading to the seizure. To 
quantify this difference, we fit a line to preictal and interictal cHFO trajectories using 
least squares linear regression. We compared slopes of these lines within and across 
patients with the Wilcoxon signed rank test and further compared their overall 
distributions for different channel groups with the Kolmogorov-Smirnov test.  
For both analyses, we used an unbiased, data-driven approach to identify natural 
clusters of outliers in the distributions by applying a kernel density estimator to the 
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population distribution, then identifying local minima that distinguished any anomalous 
cluster, similar to our previous methods [86]. These minima were used as thresholds to 
identify putative responders.  
Results 
Our automated HFO detector was run on the iEEG data of 30 patients (15 male, 15 
female) from the University of Michigan health system. Patients in the study represented 
a diverse clinical cohort with a variety of ages, seizure foci, and epileptic etiologies. In 
total, > 11.4 million HFOs from nearly 2,000 iEEG channels were detected and analyzed 
across > 225 days of iEEG data. Further patient summary can be found in Table 1.  
Comparison of mean HFO rates: We first compared mean HFO rate across all the 
temporal epochs, an analysis that previously has been restricted almost exclusively to 
interictal periods. As shown in numerous prior studies, we found that SOZ channels had 
significantly higher mean rates than OUT channels for interictal and preictal epochs 
(Figure 3A, P < .001). Similar results occurred in ictal and postictal epochs (not shown, 
P < .001). We also compared mean HFO rates in different epochs across our population 
(not shown); ictal periods had much higher HFO rates than all other epochs (SOZ, OUT: 
P < .001), whereas postictal rates were quite variable among different patients but on 
average tended to be slightly higher than either interictal or preictal epochs, although 
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this did not reach significance in all groups (data not shown). The primary analysis was 
to compare inter- and preictal HFO rates. When averaged across all patients, there was 
no statistically significant difference in mean HFO rate between interictal and preictal 
epochs for either SOZ or OUT channel groups. In certain patients, however, we noticed 
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FIGURE 3: Population comparisons of mean HFO rate. A, Population box plots of mean high-
frequency oscillation (HFO) rate comparing interictal (INTR) and preictal (PRE) epochs, organized by 
channel group (seizure onset zone channels [SOZ], nonepileptic channels [OUT]). No statistical 
difference in mean HFO rate during interictal and preictal periods was found; mean rate in SOZ 
channels was significantly higher than OUT channels for all epochs (ictal and postictal, not shown: P < 
.001). Statistical comparisons performed (Wilcoxon signed rank test) are denoted by brackets at the 
top of each panel; asterisks show statistical significance, ***P < .001. Differences in raw data during 
interictal and preictal epochs are visualized per patient between box plot groups: “mean rate 
responders”—patients with increased difference in preictal rate in SOZ channels—are shown with red 
lines, whereas other patients are shown with black lines. B, Smoothed and binned population 
distributions of the difference in preictal versus interictal mean HFO rate are shown by channel group. 
OUT channels (blue) are unimodal, but SOZ channels are bimodal and show the presence of a 
“mean rate responder” patient subset (red), each having a difference in rate of 0.58 HFOs/min/ 
channel . 
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SOZ. This led to the possibility that specific patients might have large differences 
between inter- and preictal HFO rates that are not seen when averaged across all 
patients. We plotted the distribution among all patients of the difference between 
preictal and interictal rates for both channel groups. As shown in the histograms of 
Figure 3B, the distribution for OUT channels is centered at zero and is unimodal. In 
contrast, the distribution for SOZ channels appears significantly skewed to the right, 
with several patients comprising the right tail of the distribution. This suggested that a 
distinct subset of “responder” patients in our cohort had significant in- creases in preictal 
HFO rates in the SOZ. Although these patients were too few to allow statistical tests to 
find strong independence of the SOZ and OUT distributions (Kolmogorov-Smirnov test, 
P = .072), they are clearly outliers in the SOZ distribution. The threshold to identify 
these outliers (first local minimum in the distribution of SOZ channels) was 0.58 
HFOs/min/channel, yielding seven total “mean rate responders”—individuals for whom 
the difference in mean HFO rate for preictal and interictal epochs was much higher than 
the rest of the population. Patients who are within this subset are marked in Table 1 and 
labeled red in Figure 3A.  
Comparison of continuous HFO rates: We used the Nelson-Aalen hazard rate 
model to estimate HFO rate as a continuous function of time (cHFO rates). The result of 
this analysis for a single patient is shown in Figure 4, which superimposes the interictal 
and preictal cHFO rates for visual comparison. Calculating the cHFO rate creates a 
time-dependent function, which we evaluated mathematically (see next section). We 
first made visual observations of these functions, comparing the cHFO trajectories 
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between interictal and preictal periods. As seen in Figure 4, this patient's preictal cHFO 
rate is generally higher than the interictal rate.  
In our visual observations, we saw significant temporal variability in preictal cHFO 
trajectories within our patient cohort across channel groups and epochs. We identified 
patients with preictal cHFO trajectories that were similar to interictal ones (examples in 
Figure 5A). There were patients with increased preictal cHFO activity over interictal 
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FIGURE 4: Example cHFO rate analysis for single patient. Example of continuous high-frequency 
oscillation (cHFO) rate analysis (Nelson-Aalen hazard rate estimate) for a single patient across 
multiple seizures, comparing preictal (blue) and interictal (green) epochs. This patient's preictal cHFO 
rates were on average higher than interictal rates. The scaled heatmap of cHFO rates (A) shows the 
contribution of individual channels to estimates computed from seizure onset zone channels (SOZ; B) 
and nonepileptic channels (OUT; C). Plots beneath B and C both show cHFO trajectories by individual 
seizure (without interictal reference). cHFO rate is defined as HFOs per minute per channel and is 
shown in the top rows of B and C with ±1 standard deviation (dotted lines). Yellow rectangles show the 
1-minute ictal buffer, and red rectangles indicate the clinical duration of a given patient's longest 
seizure. The peri-ictal window was truncated for display purposes at 40 minutes. 
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FIGURE 5: Variability of observed preictal continuous high-frequency oscillation (cHFO) rates. A, Many patients 
had few significant differences between interictal and preictal cHFO rates (example patients given in A1 and 
A2). B, Other patients displayed increased preictal cHFO trends relative to those of interictal periods; of these, 
periodic bursts of HFOs were evident in some (B1), whereas others showed more sustained increases in 
preictal HFO rates over interictal (B2). C, Two patients with gradually increasing preictal HFO rates were also 
identified. D, Examples of individual seizures in different patients, whose preictal cHFO rates also gradually 
increased toward onset, similarly to the average preictal trends of C. Here, cHFO rate is defined as HFOs per 
minute per channel. Visual formatting of all subfigures herein is the same as shown in Figure 3B,C. OUT, 
nonepileptic channels; SOZ, seizure onset zone channels; SZ, seizure.	
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cHFOs, and others had more sustained increases (Figure 5B). We also identified 
patients with preictal cHFO trajectories that appeared to increase gradually, leading to 
seizure onset (Figure 5C). These preictal trends were averaged across many seizures, 
but were also observed prior to individual seizures (Figure 5D). Even limited to visual 
inspection, these various changes were visible in at least 12 of the 30 patients. These 
example visual observations of preictal cHFO trends in various patients motivated 
further in-depth quantitative analysis, which we describe in detail below. Also, note that 
Figure 5 shows two patients (UMHS-0029 and -0040) in whom the HFO rate is higher in 
OUT compared with SOZ. As seen in Table 1, these were the only two patients who had 
this effect, which occurred when averaging over the entire region rather than selecting 
specific high-rate channels within the SOZ. Patient UMHS-0029 was not a responder, 
and UMHS-0040 had an atypical response described below.  
Statistical significance of temporal trends: The visual observations in the 
previous section suggested that perhaps the change in the rate as seizures approach, 
rather than simply the magnitude, was associated with impending seizures. To quantify 
the temporal trends shown in Figure 5C, we compared the cHFO rates as mathematical 
functions. We used linear regression to fit a line to the 30-minute trajectory of cHFOs in 
the average preictal and interictal windows in each patient. These values are shown as 
population box plots in Figure 6A, where we define slope (ΔcHFO rate) as the change in 
HFO rate over 30 minutes, with rate given as HFOs per minute per channel. A number 
of patients had high preictal slope in SOZ channels, whereas across the population, 
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interictal slopes were close to zero. We compared the distributions with a signed rank 
test, which takes pairwise differences between the preictal and interictal periods for 
each patient. The SOZ had a significant increase in slope (median ΔcHFO rate, 
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FIGURE 6: Population comparisons of cHFO rate regression slopes. A, Population box plots of 
regression slopes fitted to continuous high-frequency oscillation (HFO) rates of interictal (INTR) 
and preictal (PRE) epochs, organized by channel group (seizure onset zone channels [SOZ], 
nonepileptic channels [OUT]). As a population, increased preictal slopes were observed only in 
SOZ channels (*P < .05, Wilcoxon signed rank test). Differences in raw data during interictal 
and preictal epochs are visualized per patient between box plot groups; “slope responders”—
patients with increasing preictal continuous HFO (cHFO) rates in SOZ and OUT channels—are 
shown with red and blue lines respectively, whereas other patients are shown with black lines. 
B, Smoothed and binned population distributions of preictal cHFO regression slopes are shown 
by channel group; both SOZ and OUT distributions are bimodal. OUT slope responders (blue) 
have a slope threshold of +0.41 over 30 minutes, and SOZ slope responders (red) have a 
slope threshold of +1.08 over 30 minutes. Here, we define cHFO regression slope (ΔcHFOrate)as 
the change in HFO rate over 30 minutes, where HFO rate is defined previously as HFOs/ 
minute/channel.  
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(median ΔcHFO rate, PRE−INTR= 0.01, P = .15). As seen in Figure 6A, the differences 
were primarily due to certain patients with higher rate who were different from the rest of 
the group. To identify these potential outliers, we used a strategy similar to that shown 
in Figure 3B; we made a histogram of preictal slopes, fit them with a kernel density 
estimator, and looked for natural thresholds. In this case, the preictal distributions were 
statistically different from interictal ones for both channel groups (Kolmogorov-Smirnov: 
SOZ, OUT: P < .05, P < .01). The threshold for outliers, that is, “responders,” was OUT 
ΔcHFO rate= +0.41, SOZ ΔcHFO rate = +1.08. This gave a total of four patients in the 
“SOZ slope responder” subset, and five in the “OUT slope responder” 
subset (individuals marked in Table 1, and colored lines in Figure 6A). The responders 
were chosen solely on the basis of their preictal slopes being outliers, but note that the 
difference with interictal ΔcHFOrate,PRE−INTR in each case was also very high. We 
thus conclude that the preictal change in cHFO rates is a novel potential biomarker of 
seizure onset.  
Relationship of responders with clinical metadata:	We evaluated whether any of 
the three responder groups (mean rate, n = 7; SOZ rate, n = 4; OUT rate, n = 5) were 
correlated with clinical factors from Table 1. Of these responders, four had International 
League Against Epilepsy class I outcomes, four had class II, and three did not have 
resections (Table 1). We could not find any consistent demographical or etiological 
factor that was associated with a particular “responder” subset of patients; the rate of 
class I outcomes was similar to that of the whole group, and there were not enough 
patients to have sufficient power to identify specific differences in other factors such as 
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location and pathology. We analyzed whether these results in 30 patients would be 
likely to apply to the larger epilepsy population. We evaluated this with a binomial 
confidence interval, with 30 samples and 11 successes (“responders”); the 95% 
confidence interval is 20%-56% (6-16 patients). Considering that as low as 38% of 
patients with refractory epilepsy achieve lasting seizure freedom after surgery, [94], [95] 
we feel this responder rate is likely to have significant clinical impact as a biomarker. It 
is highly likely to be present in a large number of patients in larger studies.  
Discussion 
We performed a systematic analysis of time-varying HFO rates in a large cohort of 
patients with refractory epilepsy, robustly comparing interictal and peri-ictal rates for the 
first time. Our analysis of mean HFO rate found no difference between preictal and 
interictal rates at a population level. Despite this, we used a data-driven approach to 
identify a putative subset of patients who are “mean rate responders,” in whom there 
was a large difference between preictal and interictal rates. We also found that mean 
HFO rate was highest in SOZ channels, which corroborates existing findings that 
interictal HFOs localize epileptic tissue, [35], [43], [96] although we have confirmed it for 
preictal, ictal, and postictal epochs as well. Mean ictal HFO rates were significantly 
higher than rates for other epochs, a finding also supported in the literature [56], [97], 
[98]. 
Prior HFO work has been based upon average rates over long windows (i.e., 10 or 
30 minutes). Here, we investigated peri-ictal HFO trends as a continuous function of 
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time (cHFO rate), which estimates the “hazard rate” of HFOs occurring at any given 
moment in time. Despite little evidence of population-wide stereotypy, this revealed 
many varied and unique temporal patterns of peri-ictal cHFO trajectories among 
individuals. In our statistical analysis of cHFO rates, we compared the relative 
magnitude of preictal and interictal cHFO trends by their linear slope and again used 
their underlying distributions to identify two subsets of patients (“SOZ slope responders” 
and “OUT slope responders”) with increased preictal cHFO activity relative to other 
patients.  
These results are supported by previous findings, although there have been 
relatively few papers dealing with the effects of preictal HFOs. Early work found that 
HFOs had significant preictal changes in small cohorts of patients [55], [56]. Other 
studies investigated high-frequency activity, but not necessarily discrete HFOs, and 
found similar results. One found that increases in 60-100 Hz power preceded seizure 
onset by as much 20 minutes in patients with refractory neocortical epilepsy [74]. 
Another showed that a predictive classifier of preictal state performed well in a subset of 
seven of 53 patients, each of whom showed distinct changes in preictal high-frequency 
activity that were coupled with slower brain rhythms [99]. The authors noted that their 
algorithm might have been successful in more patients if their cohort were more 
homogenous. Our work has quite similar results with HFOs; in our clinically diverse 
population, there were distinct subsets of patients in whom HFO rate reliably increased 
prior to seizures, albeit in different but complementary ways.  
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We did not identify any factors to predict which patients would be “responders”; 
however, it is important to point out that this is not a major concern, because the 
potential use case for HFOs as a temporal biomarker would require intracranial 
monitoring, which can be used to identify and train an algorithm post hoc. Thus, we do 
not anticipate that clinical metadata alone could be used to stratify which patients could 
be candidates. However, we did a deep analysis of the OUT slope responder group, as 
this indicated patients in whom HFO data suggested possible epileptic pathology 
outside of the SOZ. UMHS-0026 and -0032 were responders in all three groups, 
suggesting HFOs were strong biomarkers across all recorded channels. The other 
three, however, were only OUT slope responders. Two of them (UMHS-0025 and -
0040) had secondary foci identified by the treating clinicians that were not included in 
the final SOZ channels. The other (UMHS- 0027) had seizures with diffuse onsets. 
From this cohort, we hypothesize that high preictal change in HFO rate may be as- 
sociated with the seizure-generating tissue, and may suggest an independent method of 
using HFOs to identify the epileptogenic zone. In other words, the OUT slope 
responders may indicate a previously unrecognized method to use HFOs to identify the 
epileptogenic zone.  
This analysis has some clear limitations. HFO occurrence is not a linear 
phenomenon, so applying a linear regression to the rate cannot capture the complex 
brain dynamics that produce it, and we make no claim that it was the “best fit” to the 
data. This function was chosen as the simplest method to characterize a generic 
increase in HFO rate during the preictal period across patients. Our goal was to 
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investigate gradual changes in preictal HFO rate across many seizures; accounting for 
nonlinear factors that would better model these variable cHFO trends was beyond the 
scope of this study. This analysis was designed to determine whether HFO rates were 
related to seizure onset, but was not designed to “predict seizures,” as it averaged 
preictal behavior across many seizures. Furthermore, this work analyzed only the HFO 
rate; there are numerous additional features of the HFOs such as amplitude, spectral 
content, and duration [100] that will enrich this analysis in future work. There is also 
evidence of preictal EEG changes that may be applicable to HFOs, [56], [81], [101] and 
seizures themselves undergo changes in dynamical states, which may also affect HFOs 
[13], [102], [103]. These varied features provide a rich environment for future analyses, 
using robust methods to compare interictal and preictal data, to assess HFOs as a 
potential seizure prediction biomarker [59], [60].  
Conclusion: Our investigation found that peri-ictal HFO rates and trends vary 
significantly across patients and even within individuals. We found a subset of patients 
in whom HFOs could be a valuable tool to identify the preictal state. This potential 
biomarker could be utilized in future studies on seizure prediction, focusing on in-depth 
characterization of interictal variability of HFO rates and greater numbers of seizures. 
Additionally, such work could better define the role of pathologic high-frequency activity 
in the mechanisms of seizure generation and its implications for the disease of epilepsy 
as a whole.  
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Chapter III: Viability of Preictal High-Frequency Oscillation Rates as a  
Biomarker for Seizure Prediction 
Accepted for publication: Frontiers in Human Neuroscience, 12/07/2020 
Abstract 
Motivation: There is an ongoing search for definitive and reliable biomarkers to 
forecast or predict imminent seizure onset, but to date most research has been limited 
to EEG with sampling rates < 1000 Hz. High-frequency oscillations (HFOs) have gained 
acceptance as an indicator of epileptic tissue, but few have investigated the temporal 
properties of HFOs or their potential role as a predictor in seizure prediction. Here we 
evaluate time-varying trends in preictal HFO rates as a potential biomarker of seizure 
prediction. Methods: HFOs were identified for all interictal and preictal periods with a 
validated automated detector in 27 patients who underwent intracranial EEG monitoring. 
We used LASSO logistic regression with several features of the HFO rate to distinguish 
preictal from interictal periods in each individual. We then tested these models with 
held-out data and evaluated their performance with the area-under-the-curve (AUC) of 
their receiver-operating curve (ROC). Finally, we assessed the significance of these 
results using non-parametric statistical tests. Results: There was variability in the ability 
of HFOs to discern preictal from interictal states across our cohort. We identified a 
subset of 10 patients in whom the presence of the preictal state could be successfully 
predicted better than chance. For some of these individuals, average AUC in the held-
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out data reached higher than 0.80, which suggests that HFO rates can significantly 
differentiate preictal and interictal periods for certain patients. Significance: These 
findings show that temporal trends in HFO rate can predict the preictal state better than 
random chance in some individuals. Such promising results indicate that future 
prediction efforts would benefit from the inclusion of high-frequency information in their 
predictive models and technological architecture.  
Introduction 
One of the most debilitating aspects of epilepsy is the uncertainty patients feel, not 
knowing when the next seizure will occur. Though seizures themselves account for an 
extremely small percentage of an individual’s time, [66] the constant threat of a seizure 
can make the planning of normal day-to-day activities an impossibility for some [7]. This 
has led many investigators to search for methods to predict when seizure might occur. 
[12], [58], [62], [104], [105] 
While ‘seizure prediction’ has been an attractive research subject for decades, early 
efforts had many unforeseen challenges. While there was evidence that EEG changed 
in the minutes or hours before seizures, [58] it was difficult to prove that these measures 
could work prospectively. A major breakthrough occurred when rigorous statistics were 
developed—the key was to show that a given algorithm could outperform random 
chance [59], [60]. Several studies then followed using this method, and were able to 
show that intracranial EEG signals could predict the preictal state better than chance.  
[64]–[66] Critical in that work was the unprecedented collection of months of continuous 
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EEG in a clinical trial in Australia, which allowed for rigorous long-term statistics [64], 
[66]. That dataset has become a crucial tool in later work, including international 
competitions, [64] as prediction algorithms have made many further improvements [65], 
[67], [70], [106]. However, the data also have two important limitations: the data were 
acquired at low sampling rate (200 Hz) that does not allow analysis of high resolution 
EEG signals; and more importantly, since the trial ended no similar chronic recordings 
have been collected.  
Thus, while there have been many very promising results in the field of seizure 
prediction, most work has been focused on a single dataset of long term, low resolution 
intracranial EEG. The results have proven that seizure prediction is possible in many 
patients, but clearly are far from optimal. One potential avenue for further improvement 
is the possibility that higher resolution EEG could hold greater information. In particular, 
over the past 20 years it has become increasingly apparent that High Frequency 
Oscillations (HFOs) are a powerful biomarker of epilepsy [30], [35], [43]. HFOs consist 
of short (< 100 ms) oscillations in the 80-500 Hz frequency band, and require sampling 
rates of at least 2000 Hz for accurate identification [51].  HFOs are more likely to occur 
in the epileptogenic zone [35]  and may help guide surgical decisions [38]–[40], [107]. 
One relatively unexplored aspect of HFOs is that their characteristics can also change 
in the 30 minutes prior to seizure initiation in certain individuals [55], [56]. These 
preliminary studies were constrained by small patient cohorts and datasets that were 
not as specific as currently-available methods [83], [108]. Nevertheless, the evidence 
from those studies motivate using HFOs to identify the preictal state. 
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Utilizing population-level inference and a large clinical dataset, our group recently 
found several features of HFO rates that were highly correlated with the preictal state 
[109]. In that work, we averaged the HFO response over all available data per patient 
and compared the responses during interictal and preictal epochs; several patients had 
significant results. However, in order to utilize HFOs to identify the preictal state 
prospectively, a different analysis is necessary. The HFO response in a given segment 
of data must be compared individually to that of other segments, rather than in 
aggregate as in that prior work.  
Robust implementation of seizure detection algorithms requires several months of 
continuous recording, as was accomplished by the Neurovista trial in Australia [66]. 
Such data with sufficient sampling rate to detect HFOs is currently impossible to attain. 
Until such devices are available, the only alternative is to utilize inpatient intracranial 
EEG monitoring, which lasts less than 2 weeks. Although such data are vastly inferior, 
they are also the only current option. Until implantable devices with >1000 Hz sampling 
rate are available, the role of HFOs in the specific context of seizure prediction must first 
be evaluated using only the limited intracranial monitoring data available, which is our 
goal herein. 
With this study, we evaluate the preliminary usefulness of HFOs in patient-specific 
seizure prediction. We employ state-of-the-art automated HFO detection methods on 
the entire recorded intracranial EEG data of a clinically-diverse cohort of 27 patients. 
With more than 10 million detected HFOs in this dataset, we use various features of 
HFO rates as predictors in patient-specific preictal classification models. With robust 
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machine learning methods and statistical techniques to validate our results, we find that 
10/27 patients have excellent classifier performance. These results are limited due to 
the short recording periods, but were very promising. While the technology does not yet 
exist that would allow a full prospective analysis using high resolution data, these 
results motivate future studies that incorporate such technology in the next generation 
of seizure prediction devices. 
Methods 
Patient population: To form our patient cohort, we looked at all patients with 
refractory epilepsy who had undergone intracranial EEG (iEEG) monitoring at the 
University of Michigan from 2016 – 2018. In order to ensure that sufficient data was 
available for training and testing our models, we required patients with the following: 1) 
a defined seizure onset zone, 2) at least three recorded seizures that were each 
preceded by non-zero HFO rates, and 3) the availability of at least 24 hours of data; 
applying these criteria to the 32 available patients resulted in 27 patients. The study was 
approved by the local IRB, and all patients in the study consented to have their EEG 
data de-identified for later analysis. Of note, all data were acquired under standard 
clinical procedures, and the current work was done retrospectively: no data from this 
research had any effect on the clinical care. Further summary of the patient population 
is found in Table 2. 
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TABLE 2: Clinical data for second study. Abbreviations: M/F: male, female, L/R: left / right, T: temporal, P: parietal, F: 
frontal, Occ: occipital, DNET: dysembryoplastic neuroepithelial tumor, NF1: neurofibromatosis type 1 tumor, NR: not 
resected, CD: cortical dysplasia, MTS: medial temporal sclerosis, PVNH: periventricular nodular heterotopia, PMG: 
polymicrogyria, VNS: vagal nerve stimulator. 
 
(hemisphere, (#/min./channel) (window duration, min.)
region) total ECoG depth SOZ (hours) SOZ OUT total used training testing 30 15 10
UMHS-0018 41 M Ib L F CD 32 0 32 4 59.8 108,510 4.18 0.54 3 3 2 1
UMHS-0019 59 F II R T Gliosis 106 106 0 2 168.8 170,946 2.30 0.19 5 3 2 1
UMHS-0020 45 F II R T MTS 25 0 25 9 171.2 54,254 0.38 0.12 7 7 5 2
UMHS-0021 30 M II R T
Gliosis, PVNH, 
PMG
46 0 46 13 179.5 394,398 1.98 0.50 9 7 5 2
UMHS-0023 29 M NR L T, P PVNH / Neuropace 69 41 28 29 164.3 390,134 0.86 0.37 20 9 6 3
UMHS-0024 31 M NR L, R T Neuropace 75 55 20 16 177.2 1,649,380 3.40 1.71 28 11 7 4
UMHS-0025 17 F II L T Gliosis 20 0 20 5 207.7 270,125 1.75 0.86 10 5 3 2
UMHS-0026 22 F NR R T PVNH 52 0 52 3 246.2 382,201 1.28 0.45 40 10 7 3 X X X
UMHS-0027 26 M NR L Diffuse VNS 91 81 10 3 205.2 1,601,359 1.90 1.41 97 11 7 4
UMHS-0028 14 F I R T Tumor: Glioma 53 47 6 5 79.7 140,782 2.95 0.42 7 6 4 2 X X X
UMHS-0029 48 M NR L T, Occ. Neuropace 91 91 0 22 226.3 847,560 0.60 0.71 14 7 5 2
UMHS-0030 5 M III L T MTS, Gliosis 100 100 0 2 146 330,614 0.98 0.56 33 21 14 7 X X
UMHS-0031 13 M I L T
Gliosis, Tumor: 
NF1
99 99 0 6 180 263,676 1.17 0.39 9 4 3 1
UMHS-0032 41 F I R F CD 32 0 32 3 184.3 295,865 3.79 0.96 8 6 4 2
UMHS-0033 5 F II R Ins. CD, Gliosis 74 0 74 4 120.7 233,883 1.40 0.38 28 8 5 3 X X
UMHS-0034 33 F I R F Gliosis 32 0 32 11 136.3 448,718 2.58 1.26 17 16 11 5 X
UMHS-0035 50 F I L T Gliosis 57 57 0 2 162.7 108,147 0.73 0.21 7 4 3 1 X
UMHS-0036 43 M NR L, R T CD / Neuropace 54 0 54 2 172.5 347,928 1.34 0.60 18 12 8 4
UMHS-0039 47 M NR R P CD / Neuropace 90 0 90 10 155.2 266,422 1.02 0.23 19 9 6 3
UMHS-0040 14 F I L P CD, Gliosis 63 55 8 8 196.7 323,180 0.38 0.66 7 7 5 2 X
UMHS-0041 32 F I R F CD 71 0 71 9 176.5 43,350 0.27 0.04 36 3 2 1
UMHS-0043 28 M II R T Gliosis 86 0 86 9 182.2 386,967 1.34 0.42 46 16 11 5 X X
UMHS-0044 45 F NR L T, P Neuropace 76 0 76 6 170.2 414,195 1.29 0.47 13 5 3 2
UMHS-0045 17 F NR L, R T Neuropace 94 0 94 15 331.5 631,551 0.79 0.25 6 6 4 2 X
UMHS-0046 23 F I L F CD 30 0 30 9 139.3 16,575 0.15 0.04 17 5 3 2
UMHS-0048 22 F NR L, R T Neuropace 86 0 86 8 141.8 404,972 2.76 0.33 23 8 5 3 X X X
UMHS-0049 53 F NR L, R T Neuropace 94 0 94 15 176.8 287,303 0.98 0.16 17 5 3 2
TOTALS / averages 1798 732 1066 230 4658.6 10,812,995 1.58 0.53 544 214 143 71 5 8 6
Pathology / 
implant type













Mean                    




Number of  seizures
 
  41 
Data acquisition: All intracranial recordings were sampled at 4,096 Hz with a 
Quantum amplifier (Natus Medical Inc., Pleasanton, CA); the electrodes implanted for 
monitoring consisted of subdural grid, depth and stereo-EEG electrodes, as deemed 
appropriate for each patient during standard clinical care. All recordings were 
referenced to a lab-standard instrument reference placed midway between Fz and Cz 
when first recorded, and then were re-referenced for HFO detection using common 
average referencing [86], which was applied to all electrodes of the same type, e.g. all 
depths or all grids or strips together.  The treating epileptologist determined which 
channels comprised the seizure onset zone (SOZ channels), as well as the onset and 
offset times of all seizures; we obtained these metadata through the official clinical 
report for a given patient. Channels within the resected volume of tissue (RV channels) 
were identified and labeled through consultation with the neurosurgeon and by pre- and 
post-op imaging comparisons if available. Any channel that was not labeled as an SOZ 
or RV channel was labeled as an OUT channel. Note that a seizure prediction algorithm 
should have knowledge of the SOZ and OUT channels available, as it must be trained 
on previous seizures and would be implemented after these studies are completed. It is 
also important to note that the SOZ is what was determined by the reading clinician and 
does not depend upon being the true epileptogenic zone. We incorporated the analysis 
of OUT channels as a conservative way to account for diagnostic uncertainty and see if 
other channels also had useful information. Channels labeled as RV that did not overlap 
with the SOZ were not used in our analysis, in order to maintain a more conservative 
analysis.  
 
  42 
Data analysis: All data analysis was conducted with custom MATLAB (Mathworks, 
Natick, MA) and C++ functions and scripts. As described in detail below and shown in 
the block process diagram of Figure 7, this analysis consisted of several steps: first, 
automated HFO detection was performed on all patient data. Then, several features 
across consecutive time windows of varying duration were computed from HFO rates. 
These features were used to train a logistic regression model to distinguish preictal 
versus interictal states. The algorithm was cross validated with held-out data and 
compared versus random chance. Model performance was quantified using ROC 
curves.    
Automated HFO detection: All HFOs were identified with a validated automated 
detector [86] with additional modifications described further below. In summary, this 
detector is based upon the original ‘Staba’ RMS-based detector [52] which then 
increases the specificity by redacting detections that overlap in time with several EEG 
artifacts such as sharp transients, electrical interference and noise, and artifacts from 
signal filtering. To further increase HFO specificity,  we excluded detected events with 
waveforms consistent with features of muscle (EMG) artifact, using another validated 
algorithm [85] as in our previous work [109]. Of note, these algorithms have previously 
been shown to be similar to human reviewers [86], [110].  
We also modified the data processing pipeline of our automated detector to ensure 
that it functioned appropriately within the unique constraints of seizure prediction. Most 
automated detectors operate by processing incoming EEG data in successive epochs of 
fixed length, e.g. 10 minutes, and then assess the background activity of the entire 
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epoch to determine a threshold for detecting HFOs within that epoch. That process 
cannot happen in real-time nor (pseudo)prospectively, because evaluating a potential 
HFO at a specific point in time requires knowledge of background activity that has yet to 
occur. Such a process would not be possible for prospective seizure prediction, in which 
there should be no knowledge of the future. To address this constraint, we modified the 
FIGURE 7: Block process diagram for study analysis. Schematic diagram showing overall data analysis 
workflow. (A) General analysis workflow. After automated HFO detection, continuous HFO rates (cHFO 
rate) are computed in both the SOZ and OUT channel groups. Next, several statistical quantities (features 
of HFO rate) are computed from cHFO rates in three 'feature windows' of different durations: 30-, 15-, and 
10- minute feature windows. After labeling this feature data as either preictal or interictal, observations 
that remain after an exclusion process are randomly divided into training and test data sets. Training data 
is used to train predictive LASSO logistic regression models, which are then tested with unseen testing 
data. The performance of each model with this testing data is assessed by computing the test AUC value, 
which, when averaged over 10x cross-validation runs for each of the three feature windows, are finally 
compared across patients; these results are visualized in Figure 9. (B) Example HFO detection, 
'responder' patient UMHS-0040. The HFO waveform is displayed on the left, while its time-frequency 
decomposition (computed with the Morse wavelet) is visualized on the right. (C) Example of cHFO rates 
computed for patient UMHS-0040. Continuous HFO rates (cHFO rate - defined as HFOs / min / channel) 
are computed in both the SOZ and OUT channel groups separately. The rate features used in the 
proceeding Table D are computed from these cHFO trajectories in 30-, 15- and 10-minute segments. (D) 
Table of rate features. Eight features are applied to cHFO rates per channel group (SOZ and OUT 
channel groups), which yields a total of 16 rate features. Abbreviations shown in this table are used 
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detection algorithm to work prospectively. First, we approximated real-time detection by 
only detecting HFOs for 30 seconds at time. Second, we still used 10 minutes of EEG to 
calculate the background, but use the previous 10 minutes of EEG data, relative to the 
end of each of data segment. In effect, the algorithm is identical to the previous one 
except it only reports the HFOs that are detected during the final 30 seconds of a 10 
minute segment, and the same process is repeated by sliding the 10 minute window 
forward 30 seconds. One outcome of this is that the first HFOs detected in any given 
data file start after the first 10 minutes of recording. With these adaptations, our 
automated HFO detection was better suited to the constraints of seizure prediction, and 
more closely resembled a real-time process. Further – and perhaps most importantly for 
preictal HFO detection – these changes also prevented seizure activity from influencing 
the detector.  We compared these results to those of the original detector, and there 
was no appreciable difference in HFO rate (data not shown), which is expected since 
there were no changes inherent to the detector itself, but rather how it was fed data.  
Computation of HFO rate: In order to investigate temporal variations in HFO rate 
with sufficient resolution, we approximated HFO rate (which we define as the number of 
HFOs per minute per channel) in both SOZ and OUT channel groups as a continuous 
function of time (cHFO rate). The cHFO rate was obtained by calculating the estimated 
HFO rate during one minute of data, then sliding the one-minute window forward one 
second and recalculating. This sliding window method approximates a continuous HFO 
rate with a 1 second time resolution. The sliding window was applied to all SOZ or OUT 
channels, which were grouped separately. For a given window segment and channel 
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group, the HFO rate was computed by summing the number of HFOs occurring across 
all channels of the same group; this value was then divided by the total number of 
channels in that respective group, which resulted in an estimate of the average cHFO 
per channel within each group (SOZ or OUT).   
Features of HFO rate: The advantage to using cHFO rate as computed above - 
rather than averaging it over longer periods - is that the temporal resolution of cHFO 
rates can reveal fluctuations and patterns in HFOs down to the scale of a second - 
which could be important in characterizing preictal trends. We quantified the temporal 
variation of cHFO rates with several descriptive statistics, including mean, variance, 
linear slope, quartiles, skewness and kurtosis across a given epoch of time. We also 
compared linear trends in cHFO rates using the slope extracted from linear regression 
applied to cHFO rates for a given epoch of time. All these values were computed 
separately in SOZ and OUT channel groups across three different epochs of time: 30, 
15, and 10 minutes, which we call ‘feature windows’. The feature windows were 
designed to account for possible differences in seizure horizons between patients, as 
we hypothesized that the duration of any preictal state would not be constant across the 
entire cohort. All features were computed from the start of a given data file in 
consecutive 1-minute intervals. Each feature window was analyzed independently of the 
others throughout the entirety of the study.  
Feature data labeling and exclusion: In machine learning, classification 
algorithms used in prediction need labeled observations of data in order to train their 
models. In this case, we label data as either interictal or preictal. Based on our prior 
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data showing HFO features changing up to 30 minutes prior to seizures, [56], [109] we 
defined the ‘preictal period’ as the 31 minutes prior to the start of the seizure. The extra 
minute occurs because we inserted a buffer of one minute just prior to seizure onset, 
which accounts for some interrater variability in seizure onset time [87].  
For each of the feature windows (10-, 15-, or 30-minutes), the ‘preictal’ windows 
were defined as the last window immediately prior to the seizure, but not including any 
of the 1 minute just before seizure onset. Because the calculations slide forward in 1-
minute steps, this means each ‘preictal’ feature window ends between 1-2 minutes prior 
to the clinician-determined seizure onset time. For each feature window length, we only 
included the one ‘preictal’ window immediately before the seizure. Because our prior 
data suggested up to 30 minutes could be considered as the physiological preictal 
period, to be conservative we ignored data during that period that was not in the 
‘preictal’ feature window. Data from those times (the two previous 10-minute windows 
and one previous 15-minute window) were discarded from both the preictal and 
interictal analysis.  
‘Interictal’ was defined as all data starting 11 minutes after a seizure until 31 
minutes prior to the next seizure, which allows a one-minute buffer for uncertainties in 
the start/stop times of the seizure. We note that some research has shown that the 
preictal state may extend beyond 30 minutes [81], [82], so this definition is conservative 
and may not capture all differences. We calculated an ‘interictal’ feature window for 
every consecutive epoch (i.e. every 30 min for the 30-min feature window; every 10 min 
for the 10-min feature window). 
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There were other limited circumstances that we excluded from analysis. To ensure 
that seizures were evaluated independently of other seizures, such as when multiple 
seizures occur sequentially, we redacted preictal observations falling within peri-ictal 
extent (11 min postictal or 31 min preictal) of other seizures. Further, we also redacted 
any observation that overlapped with periods of incomplete or missing data, which could 
result from gaps within a file or from a file’s end. Finally, considering our modifications to 
the HFO detector, any data observation overlapping with the first 10 minutes of a given 
data file was also redacted, as HFOs are not detected for the first 10 minutes. 
Logistic regression model: We used a logistic regression model to classify 
preictal versus interictal data. Logistic regression determines the probability that given 
data is from a specific labeled class, and has been used in seizure prediction studies 
previously [111]. It also has the advantage of allowing us to analyze the relative 
contributions of each feature, rather than being a ‘black box’ approach. We trained 
models for each of the three feature windows (10, 15, 30 min) using 2/3 of the data and 
then testing on the remaining 1/3.  This process was cross-validated 10 times for each 
feature window by randomly-selecting different interictal and preictal data, and re-
running the training and testing step, for a total of 30 models per patient. Random 
selection, rather than chronological, was used because of the limitations of this dataset: 
unlike in the Neurovista dataset that had months for the recordings to stabilize, [112] our 
data is limited to 2 weeks of inpatient monitoring. This unavoidably leads to some 
variability over time due to various factors such as medication taper, sleep disturbances, 
and the settling of electrodes [112]–[114]. Here, we used random selection to reduce 
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the influence of these factors on overall model performance, but this also may reduce 
the effectiveness of the model.  
In order to facilitate the models helping to determine which coefficients were most 
useful in forecasting seizures, we used LASSO logistic regression [111], [115], [116] to 
create the predictive models used in our study. Specifically, in Matlab we used the 
lassoglm function, with the following general syntax: lassoglm(XTrain, yTrain, 'binomial', 
'CV',  k), where XTrain is the feature vector, yTrain is a binary vector with ‘0’ for interictal 
and ‘1’ for preictal, and k is chosen as the number of seizures within the training data. 
This function inherently cross-validates the trained model based upon the number of 
seizures k, which reduces overfitting. In general, LASSO introduces a penalty on the 
absolute value of the coefficients, and optimizes the model by iterating through different 
penalty parameters to find the lowest error, while removing coefficients that have 
minimal effects [115]. Thus, one outcome of the training step is to identify which 
features were the most important for identification of the preictal state. 
Assessing predictive performance: Each cross-validation iteration tests whether 
the predictive model can correctly classify novel preictal versus interictal data. We 
computed the ROC curve for each iteration, then computed the arithmetic mean of all 
the areas under the curve (AUC) across all ten iterations. A random predictor would 
have an AUC of 0.5, while a successful predictor should have an AUC higher than 0.5. 
We chose a nominal threshold of 0.6 to show the minimal improvement above 0.5 that 
would be meaningful. However, that threshold is subjective so we then tested the 
significance of each AUC using bootstrapping by randomizing preictal and interictal 
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labels (n=1000). The statistical significance of these average AUC was determined by 
taking the harmonic mean of the bootstrap p-values, [117] a procedure used in meta-
analysis to combine p-values from multiple tests. Successful tests were those in which 
the average AUC was ≥ 0.6 and p < 0.05. We note that in clinical practice an AUC of 
0.6 might be difficult to implement successfully on its own; however, it is comparable 
with prior seizure prediction work in standard EEG [12], [58], [62], [104], [105].   
Results 
Our heterogeneous patient cohort was comprised of individuals with a variety of 
ages, clinical etiologies and pathologies, and seizure foci. Out of 32 original patients in 
our database, four patients (UMHS-0037, -0038, -0042, -0047) were excluded either 
because of insufficient recorded seizures or undefined seizure onset zones. One patient 
in particular (UMHS-0022) had seizures with no HFOs prior to onset; this patient was 
also excluded, which left a total of 27 patients remaining for further analysis. Across 
these 27 patients, we detected more than 10 million HFOs across over 190 total days of 
intracranial EEG recordings. Over 210 seizures and 3,800 hours of interictal data 
(average of 8 seizures and 141 hours per patient) were used to train and test our 
classification models.  
Comparison of test AUC values: We first assessed the general responses across 
all cross validation models in all patients. Over the 27 patients, with 30 models each 
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(810 total), the model successfully converged to a solution in 403 instances (49.8%). 
The non-converging solutions are easily identified because all coefficients for HFO 
features are 0, and it is obvious that the model could not be used. In such cases, we 
conservatively assigned them a testing AUC value of 0.5 (and a bootstrap p-value equal 
to 1) – the same performance as a random predictor. The remaining patient models 
were composed of linear combinations of HFO rate features. As shown in the histogram 
of Figure 8, the distribution of test AUC values for these models overall showed 













FIGURE 8: Distribution of test AUC values for tested models.This histogram of testing AUC values, 
computed for all tested models individually over all patients and feature windows, is skewed toward 
predictive performance that is better than random chance, i.e. values higher than 0.5. 
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significant variability and spread from 0.5 (AUC test - maximum: 0.97, minimum: 0.024, 
median: 0.64). The skew of this distribution toward values greater than 0.5 suggests 
that a significant portion of models that used HFO features could perform better than 
random chance at identifying the preictal period. 
We evaluated the consistency and reliability of this result within patients by 
determining if its average test AUC was at least 0.6 and if the average bootstrapped p-
value was < 0.05. These values are shown with statistical significance noted in the bar 
plots of Figure 9. We found 10 out of the 27 patients had a significant response in at 
least one of the feature windows. We denote these 10 patients as ‘responders,’ and 
their average predictive response was robust and consistent. The presence of this 
subset of patients in our cohort suggests that there are measurable changes in preictal 
HFO rate preceding epileptic seizures that deviate from interictal trends. This finding 
shows that HFOs can act as a temporal biomarker of seizure onset in some patients.  
Within the responder group, 4 were significant in only one feature window, while the 
rest had multiple. We compared the three windows (10, 15, 30 min) and found no 
evidence that the performance of one window was better than any other - either by how 
frequently it was significant in these patients, or by how high its overall performance 
was (Chi-square test: p-value = 0.61; Kruskal-Wallis test: p = 0.737). All responders and 
their significant windows are identified in Figure 9 and in Table 2. The p-values and 
associated asterisks indicating statistical significance in Figure 9 were based on 
individual bootstrap tests and not corrected for multiple comparisons.
 
  52 









































































































































































FIGURE 9: Bar chart of average test AUC values by patient and feature window. 10 individual responder patients have significant predictive performance 
(average test AUC >= 0.6, significant average bootstrap test p-value < 0.05) in one or more feature windows. The statistical significance of the bootstrap 
test per feature window is indicated with asterisks: *, **, ***; p = < 0.05, < 0.01, < 0.001 respectively.  Note that the significance is based upon how likely 
that patient’s data could produce the given AUC by random chance, not whether the magnitude of the AUC itself is high. 
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Significance of responder predictors: We investigated which features contributed 
to the significant predictive response observed in responder patients. Overall, both the 
combination and relative magnitude of HFO features in responder models varied 
significantly between patients, feature windows, and even between different cross-
validation runs. Considering this variability, we could not evaluate feature importance 
directly by the raw coefficient values that resulted from LASSO logistic regression. 
Instead, we calculated how often a given feature was included among models - 
specifically, how often its corresponding coefficient was non-zero. In this manner, we 
considered the most commonly used features to be the most important to differentiating 
the preictal state from other interictal observations - whether its associated output 
coefficient was positive (which would indicate increased likelihood of an imminent 
seizure resulting from an increase in the feature's value) or negative (i.e. decreased 
seizure likelihood from a feature's increase). These frequencies of non-zero model 
coefficients per feature are shown by feature window in Figure 10, and are sorted in 
order from most to least common within responder models. Though we did not evaluate 
feature magnitude directly, we note that the medians of all responder SLOPE-SOZ 
features by patient and feature window were all positive, which reinforces our prior 
findings that gradually increasing HFO rates anticipate seizure onset [109].  
While there were some observed differences in which features were the most 
common between window durations, there were no statistically-significant differences in 
feature frequency across the three feature windows (Kruskal-Wallis: p = 0.64). In terms 
of the most important features, the linear slope of HFO rate in the SOZ (Slope-SOZ) 
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was most important in both the 30 and 15 minute windows. Also common among 
important features were those computed from cHFO rates in OUT channels – channels 
that might be traditionally considered as less involved in pathological brain networks. 
Yet, there were no statistical differences in frequency between SOZ and OUT channel 
features (Rank-sum tests: p = 0.34, = 0.24, = 0.42 for 30, 15 and 10 minute windows 
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FIGURE 10: Relative importance of rate features in responders. Bar chart showing the relative frequency 
of each rate feature for only significant responder models. The features of HFO rate most important to 
discerning the preictal HFO response in responders are ranked in descending order (top to bottom) 
according to how often their respective model coefficients were non-zero for a given feature window. 
Overall, the most important feature was the SLOPE-SOZ feature, which was ranked first in both 30 and 
15 minute feature windows. Also important were features in OUT channels, a novel finding that suggests 
HFOs outside epileptic tissue could still be involved in the process of seizure-generation. 
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respectively), even though SOZ features were highest ranked across feature windows, 
with an average cumulative frequency almost 14% greater than that of OUT channel 
features. This suggests that HFO rates could be used to identify the preictal state 
regardless of their location.  
Clinical factors of responders: Considering the clinical outcomes of responders, 
four were ILAE class I, two were class II, there was one class III, and the others were 
not resected. Comparing various clinical factors, there was no statistical evidence for 
differences in the composition of responder patients compared to the rest of the cohort. 
The ratio of temporal to extra-temporal seizure foci in responders was similar to other 
that of other patients (Fisher exact test: p = 0.68), and while there appeared to be a 
difference in the pathology of resected responders favoring gliosis, this was not 
significant in comparison to the rest of the cohort (Fisher exact test: p = 0.14). Despite 
lacking a clinical factor to differentiate this group from the rest of the population, based 
on our results, we estimate the relative proportion of responders in a given population is 
19-55% of patients (95% binomial confidence interval with a test sample of 10/27), 
which demonstrates that patients with potential for significant HFO rate predictive 
performance could comprise a substantial portion of a large clinical cohort.  
Discussion 
In this first-of-its-kind study, we combined advanced automated HFO detection with 
the intracranial data of a large clinical cohort to investigate the potential use of high-
frequency oscillations in seizure prediction. Across patients, we found significant 
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variation in the ability of time-varying properties of HFO rate to discern a preictal state. 
After applying a statistical benchmark to the average predictive performance of all 
models across our cohort, a subset of patient responders was identified that had 
consistent predictive performance better than random chance. The identification of 
these 10 individuals represents a novel finding and is our study’s most important result. 
It provides firm support that high-frequency oscillations can function as a temporal 
biomarker of seizure onset, and additionally gives preliminary evidence that seizure 
prediction using HFOs is not only possible in a clinical context, it can hold significant 
potential for certain patients.  
Another important outcome is the identification of which HFO rate features are the 
most useful. Ranked by their frequency in responder models across multiple windows of 
time, the most important predictive features of HFO rate included linear slope, variance, 
and the first quartile cHFO rate within the feature window. The most common feature 
was the linear slope, which measures gradual changes in HFO rate (either increasing or 
decreasing), suggesting that these changes are centrally important in determining if a 
seizure is imminent. One surprising finding was that even HFOs outside the SOZ were 
useful features.  Note that it is not possible to compare relative magnitude of these 
feature coefficients directly because of the considerable model variability between 
patients, feature windows, and cross-validation runs. We analyzed the 10 responders 
and found that three of them had clinical situations in which the OUT channels were 
likely to be pathological. One patient had a known secondary seizure focus not included 
in the official SOZ (UMHS-0026), while another had high HFO activity in a non-resected 
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hippocampus that was likely dual pathology from a parietal lesion (UMHS-0040). 
However, the OUT features were not restricted just to those patients, and thus our 
finding of predictive value of HFO features outside the SOZ is an intriguing finding. This 
result suggests that HFOs even outside the SOZ provide important information on 
identifying impending seizures.  
The test AUC values of responder patients we report are within the ranges 
presented in several seizure prediction studies, notably Brinkmann et al. 2016, Karoly et 
al. 2017, and Kuhlmann et al. 2018 [63]–[65]. There is one caveat to using the AUC 
metric in seizure prediction, as the inherent imbalance of interictal and preictal data can 
increase the reported specificity. In order to compare our work with other studies, 
however, this was an acceptable limitation for our analysis. While no prior work has 
evaluated HFOs for seizure prediction, there is evidence for a ‘preictal state’ [81].  HFOs 
have been shown to have different signal features [56] and changes in rate 30 minutes 
before seizures [109]. Further, some studies have shown distinct changes in high-
frequency activity preceding seizure onset; some have also suggested that HFOs could 
be linked to seizure-generating mechanisms [74].  
Despite our positive result, it must be noted that our overall methodology has a 
number of inherent constraints that limit our findings from being more widely applicable 
to seizure prediction in general. First, this analysis was based upon processing several 
minutes of data at a time (10, 15 or 30 minutes) rather than analyzing features of 
individual HFOs. There are a wide range of HFO features that could be incorporated 
into future prediction algorithms. Next, we note that ‘true’ seizure prediction would 
 
  58 
involve choosing a specific algorithm and testing accuracy prospectively, which was not 
done here. Second, this method requires HFOs to be present and enough seizures to 
develop a predictive model; five of our cohort of 32 did not meet this standard.  Finally, 
as stated before these data are limited to only 2 weeks immediately postoperatively 
during varied medication changes, which is known to be insufficient to have consistent 
EEG signals and sometimes even atypical seizures. Several of our patients had 
inconsistent results, but with so few seizures it is impossible to predict whether this 
would stabilize to an effective solution with more data. A much longer dataset under 
standard living conditions would be necessary to develop robust algorithms, but such 
data are not physically possible at present. Future work with a larger dataset could also 
incorporate additional features of the HFOs themselves (e.g. signal features such as 
frequency data), as well as previous prediction algorithms using standard EEG. This 
type of synergistic analysis on larger datasets could have much greater chance at a 
clinically-realizable seizure prediction algorithm.  
Conclusion: Our results show that HFOs can function as a temporal biomarker of 
seizure onset. We show that changes in the HFO rate are capable of identifying the 
preictal state up to 30 minutes before a seizure in some patients. As a preliminary 
study, our findings are a foundation for future work pursuing individualized seizure-
specific prediction efforts, which we envision could eventually function as a tool inside 
advanced implanted neuromodulation devices that utilize patient-specific and seizure-
specific prediction methodologies. Advancement of this HFO seizure prediction 
framework, however, will require the availability of many chronic high-sampling rate 
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intracranial recordings. While this technology does not yet exist, recent technological 
improvements have brought it closer to realization - which is sufficient impetus to further 
investigate HFOs both as a temporal biomarker of epilepsy, and as a potentially 
powerful predictor of epileptic seizures.  
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Chapter IV: Signal Characteristics of Preictal High-Frequency Oscillations in 
Refractory Epilepsy 
Abstract 
Objective: High-frequency oscillations (HFOs) have become an important spatial 
biomarker of epileptic tissue and epilepsy in general. HFO signal features vary by 
patient, and recent evidence shows that HFO rates change in time prior to seizure 
onset; both are findings with relevance to patient-specific seizure prediction. Still, HFO 
signal features have never been evaluated in the context of seizure prediction. Here we 
analyze time-varying properties of both HFO rates and signal features to fully 
investigate the consistency of the preictal HFO response in a large clinical cohort, and 
to understand additional contributions of signal features. We also highlight the practical 
application of HFOs to seizure prediction with an implementation of a seizure advisory 
system. Methods: We analyzed the HFOs of 27 patients with refractory epilepsy who 
were being evaluated for resective surgery. We characterized changes in HFO rates 
and signal features over time, and assessed their preictal and interictal differences 
using cross-validated logistic regression models, whose predictive performance we 
compared the AUC metric. The implementation of our seizure advisory system used 
these models to generate seizure probabilities through continuous time, and applied two 
iteratively-determined probability thresholds to generate three discrete seizure warning 
levels (low, medium and high) in time. The performance of the advisory system was 
 
  61 
assessed by comparing the percentage of time spent in each warning level, the 
percentage of seizures correctly identified in each warning level, as well as the average 
warning time until a seizure occurred. Results: There were 13 ‘responder’ patients out 
of 27 with significant preictal HFO characteristics. Evidence that signal-based HFO 
characteristics could improve prediction performance was overall inconclusive; but for 
some patients the magnitude and consistency of prediction performance with HFO 
signal features was significantly increased. The performance of the seizure advisory 
system was within the range of several other notable prediction studies using this 
method. Significance: These findings further reinforce and expand evidence that HFOs 
are temporal biomarkers of seizure onset. They also demonstrate that HFO signal 
features can add meaningfully to prediction for some patients. While the seizure 
advisory system was presented chiefly as a proof-of-concept, its encouraging result in 
many patients is a powerful demonstration of the potential utility of HFOs within patient-
specific seizure prediction. 
Introduction 
Approximately one third of patients with epilepsy do not respond to medication [23]. 
For these individuals, invasive resective surgery is often the only recourse to achieve 
lasting seizure freedom. Yet many still experience seizures after surgery, while others 
are not even candidates for resection [29]. Given their unmanaged seizures, these 
individuals represent a sizeable patient population whose quality of life could benefit 
significantly from an implanted therapeutic device capable of accurate seizure 
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prediction. Though these devices do not currently exist, their eventual clinical realization 
has been a driving motivation for many seizure prediction researchers, which has 
resulted in numerous milestone achievements over the past twenty years [104]. 
The field of seizure prediction is at a crossroads, however. With recent 
advancements in our understanding of seizure mechanisms, it is becoming more 
evident that seizure prediction in actual clinical practice will require patient- and seizure-
specific adaptations [12], [62]. This results from the identification of individual-specific 
factors that can influence seizure mechanisms; endogenous examples include the 
individual variation of diurnal and multiday rhythms [101], the presence of multiple 
dynamical seizure types in a single individual [13], [103], and the phenomenon of 
seizure clustering [62]. So while the direction of future work in seizure prediction is 
clear, the technology to realize its clinical translation has lagged behind [62], as there is 
still only one chronic dataset currently available for prediction research, and it was 
created nearly ten years ago [66]. Perhaps more importantly, however, a reliable 
electrical biomarker of seizure onset has yet to be identified, let alone a more useful 
patient- and seizure-specific indicator [12], [62]. 
Seizure prediction, like clinical interpretation of EEGs, is dependent upon the 
available data and how they are interpreted. Historically, these data have been limited 
to EEG signals below 100 Hz. Most EEG devices sample in this range, and clinicians 
have learned to read EEG accordingly. In fact, one study demonstrated that higher 
resolution EEG did not change clinical interpretation at all: 100 Hz was clinically 
indistinguishable from 1000 Hz [118]. Nevertheless, these electrical biomarkers of 
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epilepsy have been extremely useful in diagnosing, managing and treating the disease 
[21]. However, the introduction of computational algorithms alongside high resolution 
hardware affords a new possibility for identifying signals that clinicians cannot see. The 
discovery of high-frequency oscillations (HFOs) - which occur more frequently in 
epileptic tissue - has aided surgical decision-making, [37] and has improved resective 
outcomes for some [39]. HFOs are now an established biomarker of epilepsy and 
epileptic tissue, but their clinical use was limited until only recently – when more 
sophisticated amplifiers capable of recording high-density low-noise EEG data were 
gradually installed at major centers around the world [42], [50]. Here, the clinical 
relevance of HFOs as a spatial biomarker was somewhat dependent on the technology 
that supported it. But given the mounting evidence that HFOs are highly correlated with 
epileptic tissue [43] along with the development of efficient automated detection 
algorithms and advancing hardware technology, in this study we argue the potential 
benefit of incorporating HFOs into the next generation of seizure prediction devices.  
As justification for this argument, there is recent evidence that HFOs also function 
as temporal biomarkers of epilepsy and imminent seizure onset [109]. There is also 
evidence (presented in the study of Chapter III) that HFO rates could be useful in 
seizure prediction, especially for certain individuals. In addition to HFO rates, various 
signal features of HFO waveforms also have documented temporal aspects, as it has 
been shown that HFO signal features 1) vary in time and location over long periods, 
exhibiting patient-specific patterns [114], 2) differentiate ictal periods from other times 
[119], and 3) differentiate the dynamics of two distinct seizure onset types [72]. Though 
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this evidence suggests a potential role for HFO signal features as possible patient-
specific and even seizure-specific temporal biomarkers, it is currently unknown if these 
measures are at all useful in seizure prediction. A thorough and robust evaluation of 
HFOs in this context, however, is not possible with current technology because no 
device exists that is capable of recording high-density intracranial EEG in a chronic 
ambulatory setting. Still, the identification of a reliable patient-specific pre-seizure 
biomarker would have great clinical potential.  
In this study, we attempt the first comprehensive study on how HFO features – 
including their rates – change over time. Conceived as a significant expansion of the 
ideas and analyses presented in Chapter III, this study directly addresses the 
considerations raised above by evaluating two main objectives: 1) to investigate 
whether HFO signal features add meaningfully to both the identification of preictal states 
and seizure prediction performance, and 2) to provide a practical demonstration of the 
clinical potential HFOs could have in patient-specific seizure prediction – which could be 
vital to the continued development of this novel temporal biomarker. 
Methods 
Many of the methods used in this study are the same as those used previously in 
Chapter III. As such, brief explanations of common methods and data will be provided, 
but for further detail, please refer to the previous chapter.  
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Patient population and data: Both this study and the study presented in Chapter 
III use the same intracranial EEG dataset, which was recorded from the monitoring 
sessions of 27 patients with refractory epilepsy during the years 2016 - 2018. All 
associated patient metadata is also the same (found in Table 2), except that patient 
UMHS-0034 now has a class III surgical outcome (outcome definitions can be found in 
[120]). All patient metadata for both studies is found in Table 2.  
Data analysis: Depicted in Figure 11, the general block process for the analysis 
presented in this paper differs from the previous study of Chapter III in only a few key 
steps. Whereas the analysis of the previous study used only HFO rate information to 
create predictive models (denoted hereafter as the ‘HFO rate analysis’ ) the predictive 
features in this study encompass both rate-based and signal-based HFO information 
(together referred to later as the ‘full HFO analysis’). Further differences between the 
studies are described below.  
TABLE 3: List of full HFO features. A list of HFO features descriptions and their abbreviations, as well as 
their meta-feature names, is provided below. Note that these features are computed independently for 
SOZ and OUT channel groups, which results in a designation of either XXX-SOZ or XXX-OUT for the 
meta-features listed in the last column.  
   Meta-feature operator: 
 Feature description: Abbreviation: 
Mean / Median / Std. Dev. / 
Skewness / Kurtosis 
Rate-based features: Number of HFO detections nDets Mean-nDets, … 
 Inter-detection interval detIdi Mean-detIdi, … 
Signal-based features: HFO Duration dur Mean-dur, … 
 HFO Amplitude * (dB) ampdB Mean-ampdB, … 
 Skewness of waveform skew Mean-skew, … 
 Kurtosis of waveform kurt Mean-kurt, … 
Mean / Std. dev. / Skewness / Kurtosis:: First derivative of signal (rectified) meanD1, … Mean-meanD1, … 
Mean / Std. dev. / Skewness / Kurtosis:: Second derivative of signal (rectified) meanD2, … Mean-meanD2, … 
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Mean / Std. dev. / Skewness / Kurtosis:: Teager-Kaiser energy meanTKE Mean-meanTKE, … 
Power spectrum estimate: Amplitude at peak frequency psePkAmp Mean-psePkAmp, … 
Power spectrum estimate: Peak frequency psePkFreq Mean-psePkFreq, … 
Mean / Std. dev. / Skewness / Kurtosis:: Power spectrum estimate meanPSE Mean-meanPSE 
Power spectrum estimate: Frequency at 25% energy freqPSEnrgQ1 Mean-freqPSEnrgQ1 
Power spectrum estimate: Frequency at 50% energy freqPSEnrgQ2 Mean-freqPSEnrgQ2 
Power spectrum estimate: Frequency at 75% energy freqPSEnrgQ3 Mean-freqPSEnrgQ3 
 
Automated HFO detection and HFO feature computation: To begin, the set of 
HFOs used in this study was identical to those used in the previous study, which 
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FIGURE 11: Schematic of overall data analysis workflow. After data acquisition, 1) HFO detection is 
performed. 2) HFO features are computed from newly detected HFOs: first, rate-based and feature-based 
computations take place, then continuous representations of these features are computed. Finally, meta-
features are computed for each of the three different feature windows using the statistical operators of 
mean, median, standard deviation, skewness and kurtosis. These meta-features are also described in 
Table 3 above. After 3) data selection, labeling and exclusion, 4) logistic regression is performed with 
training and testing data over a series of 10 randomized cross-validation runs. 5) Performance 
comparisons of resulting logistic regression models are made with AUC computations. 6) Using the 
predictive models of step 4, the models with the best training AUC as well as an average model made 
from all cross-validation folds are used in the seizure advisory system. This system functions by first using 
these models to determine the probability of a seizure in time, and by applying two iteratively-determined 
thresholds TH1 and TH2, the warning level in time (which can be low, medium or high) is then determined 
from the seizure probability.  
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set of 25 signal features was assembled that we hypothesized would capture important 
temporal variations in HFOs. Listed in Table 3 above, these signal features encompass 
linear and non-linear measurements of individual HFO waveforms in both the time and 
frequency domains. The signal features of all HFO waveforms were computed at the 
time of HFO detection (a process indicated in Figure 11 as ‘signal-based feature 
detection’); prior to this, each waveform was normalized to have unit amplitude, except 
for the computation of HFO amplitude (‘ampDb’ in Table 3), which was not normalized. 
The computation of the two additional rate-based HFO features is described in the next 
section.  
Computation of continuous HFO signal features: HFOs are discrete events, but 
seizure prediction algorithms in practice are evaluated continuously in time. Thus, it was 
useful to transform HFO features into approximations of a continuous process. In this 
study, the computation of these ‘continuous’ features was identical to the method 
detailed in the HFO rate analysis of Chapter III. The only difference was the number of 
inputs to this computation; in the previous paper only HFO rate was used, whereas here 
the 25 signal-based HFO features were used (shown in Table 3), as well as two rate-
based features (the number of detections ‘nDets’, and the inter-detection interval 
‘detIdi’). As such, aggregating HFOs by channel group (either SOZ or OUT channel 
groups) resulted in 54 continuous features.  
Computation of windowed meta-features: We evaluated temporal fluctuations in 
continuous HFO features by characterizing changes in their larger distributions in time 
across three different temporal horizons, or 'feature windows'; these were 30, 15 and 10 
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minutes in width. Though this computation was identical to methods of the previous 
study, here we used a slightly different set of statistical operators to compute the final 
‘meta-features’ that would serve as inputs to logistic regression. Shown in Table 3, 
these operators consisted of the mean, median, standard deviation, skewness and 
kurtosis; they were applied individually to all continuous HFO features across the three 
independent feature windows. Overall, this computation resulted in a total of 270 ‘meta-
features’ per feature window.  
Feature labeling and exclusion: In general, the data labeling and exclusion 
processes employed in this paper are identical to those detailed in the second paper: 
interictal labels were assigned in consecutive and non-overlapping intervals, while 
preictal observations consisted of the last feature window instance just prior to seizure 
onset.  
Logistic regression model: All meta-features were used as predictor variables in 
logistic regression. The LASSO logistic regression procedures used to train the 
predictive models of this study were identical to those used in the rates analysis of 
Chapter III; for details on this specific implementation, please refer to the corresponding 
methods section of Chapter III.  
Assessing predictive performance: We assessed the predictive performance of 
models trained by LASSO regression by averaging their corresponding test AUC values 
over all cross-validation runs. We also applied a bootstrap permutations test to all 
individual test AUC, which provided validation that observed values were statistically 
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different than the performance of a random predictor. Similarly to the test AUC, these 
bootstrap p-values were also averaged over all cross-validation runs using the harmonic 
mean, which has been recommended for averaging the p-values of multiple dependent 
tests [117]. As in Chapter III, we used nominal statistical criteria to determine 
‘responder’ patients: these individuals had at least one feature window with average test 
AUC ≥ 0.60 and corresponding average bootstrap p-values < 0.05. Finally, we used 
non-parametric statistical tests to compare responder and non-responder prediction 
performance. We also used these tests to compare the predictive performance of this 
study’s full-feature HFO analysis with the prior HFO rate analysis of Chapter III. Except 
when indicated, all statistical tests were corrected appropriately for multiple 
comparisons with the Bonferroni correction. 
Implementation of seizure advisory system: The functionality of our advisory 
system is based on notable past work [66], [69]. Those systems were designed to alert 
the user of seizure risk through time by displaying one of three discrete warning levels: 
low, medium, and high risk. In a general sense, the system operates in a continuous 
fashion through time, and for a given moment, it assesses the probability that a seizure 
will occur before its next update ( "!"($) ). It then determines the corresponding warning 
level ( &!"($) ) to be displayed by applying two thresholds ( 'ℎ#, 'ℎ$	) to the current 
seizure probability. In prospective or pseudo-prospective prediction (which describes 
prospective prediction methods using previously obtained data) these thresholds are 
determined and updated dynamically in time, as new information about previous 
seizures is obtained. If the number of seizure observations are limited – as they are in 
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this study – these thresholds are determined only once after all data are collected,  
though this can potentially weaken an outcome’s significance by introducing overfitting. 
Despite this, we chose the latter method of threshold evaluation for this study because 
of limited available data, and because of the original aim of demonstrating (and not 
proving) the potential of HFOs in practical seizure prediction. 
Working within the constraints of this latter threshold evaluation method, we still 
wanted to portray a comparison between what could be considered the advisory 
system’s best possible outcome and how it might actually perform in real-world settings. 
To show precedent in the literature for such a comparison, an analogous approach was 
used recently in [69].  
In this study, the approach with the ‘best possible outcome’, (referred to as the 
average model) was evaluated with knowledge of all data and seizures. Specifically, the 
probability of a seizure in time ( "!"($) ) was derived from the output of a single ‘average 
predictive model’ per feature window; this was created simply by averaging the 
coefficients of individual models over all 10 cross-validation runs. As each cross-
validation fold randomly selected training and testing data from the full temporal extent 
of a dataset, this ‘average’ model was thus likely trained on all seizures and data.  
The model selected to show more realistic real-world performance was simply the 
model with the highest training AUC per feature window, (referred to as the best-trained 
model hereafter). This choice of training AUC did not bias the advisory outcome with 
knowledge of how the model actually tested on held-out seizures and data, and so, 
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these models were effectively trained on only 2/3 of all data and seizures. Except for 
associated warning thresholds, which were optimized over all data, these advisory 
outcomes include performance for held-out seizures, which more closely resembles 
pseudo-prospective seizure forecasting.  
In the approaches of both average models and best-trained models, the model 
output used to form the seizure probabilities over the entire dataset was created by 
inputting all associated meta-feature data, which, for the purposes of the advisory 
system, were evaluated continuously in time in 1-minute intervals. These data were also 
subject to the same exclusion procedures as described before, though their 
computation did not require interictal and preictal labels. Once we determined the 
seizure likelihood in time as above, we iteratively optimized the warning thresholds ('ℎ#, 
'ℎ$) over a large range of values first by determining various performance metrics for 
each threshold pair (described further below). Optimal threshold pairs were then 
identified as those that satisfied the four following conditions: 
+#: maximize the number of seizures correctly identified in high warning  
+$: maximize the percentage of total time spent in low warning 
+%: the number of seizures identified per warning level must monotonically decrease 
going from high to low warning 
+&: the percentage of total time spent per warning level must monotonically 
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Once the thresholds 'ℎ# and 'ℎ$ were determined as above, the warning level at 
time t –  which would last for a duration of one minute until the next probability update –  
was given by the following:  
&!"($, 'ℎ#, 'ℎ$) = -
0	(low), 													"!"($) < 'ℎ#
	1	(med), 'ℎ# ≤ "!"($) < 'ℎ$
2	(high) 'ℎ$ ≤ "!"($)													
		. 
We used a number of performance metrics to determine the warning thresholds as 
above, and to make final performance comparisons between patients and the two 
different advisory approaches. These included the number of seizures identified per 
warning level, where, for each seizure, the value of the warning level just prior to 
seizure onset was recorded; these values per warning level were then summed over the 
dataset to produce the total number of seizures identified per level. The percentage of 
total time per warning described in conditions +$ and +& above was calculated without 
redacted data. Lastly, we also compared the average prediction horizon for seizures 
correctly identified in high warning (which would constitute a true positive detection), 
which we defined as the duration of time spent in high warning just prior to seizure 
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Results 
Out of all patient models (810 in number), 387 successfully converged under 
LASSO regression (47.8%). Models that failed to converge with HFO features – either 
signal-based or rate-based – were conservatively assigned test AUC values of 0.5, and 
bootstrap test p values of 1. Of the 387 models that converged to a solution involving 
HFO signal features, there was significant variability in their predictive performance 
(HFO features: AUC test minimum - 0.032, maximum - 0.989, median - 0.651, 
interquartile range: 0.294 ).  
Average test AUC: We identified models with minimally significant predictive 
performance by applying the following criteria: AUC test ≥ 0.6 and bootstrap p value < 
0.05. This was also applied to average test AUC values as well as average bootstrap p 
values, which were averaged using their harmonic mean. These average test AUC 
values for each patient and feature window are shown in the bar plot of Figure 12.  With 
the statistical criteria above, we identified 13 ‘responder’ patients overall with significant 
predictive performance in at least one feature window; utilizing a 95% binomial 
confidence interval, this means that we could reasonably expect between 29.3% - 
67.0% of a larger patient population to be responders. 
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FIGURE 12: Bar chart of average test AUC values by patient and feature window. 13 individual responder patients have significant predictive 
performance (average test AUC ≥ 0.6, significant average bootstrap test p-value < 0.05) in one or more feature windows. The statistical significance 
of the bootstrap test per feature window is indicated with asterisks: *, **, ***; P < 0.05, < 0.01, < 0.001 respectively.  Note that the significance is 
based upon how likely that patient’s data could produce the given AUC by random chance, not whether the magnitude of the AUC itself is high. 
 
  75 
Differences across feature windows: Considering the three different feature 
windows, there were 10 patients with significant average AUC in the 10 minute window, 
while 8 and 5 responders respectively had significant average AUC in the 15 and 30 
minute feature windows. There were no statistically significant differences among 
feature windows that would suggest a particular window was more frequently significant 
than any other (Chi-square test: P = 0.31).  
Comparing the performance of each feature window by the average AUC of 
significant responder models, the thirty minute window appeared to perform better than 
the 10 minute window (median AUC in 30 minute window: 0.806, 10 minute window: 
0.670), however, this difference was not significant after correcting for multiple 
comparisons (2-sided rank-sum test, P = 0.0280). There were, however, significant 
differences in the significance of the bootstrap test p-values across different windows 
(Kruskal-Wallis: P< 0.05): p-values in the 15 minute window were significantly different 
(lower) from those in the 10 minute window (2-sided rank-sum test, P<0.05).  
Comparing predictive performance of HFO features versus rates: We 
compared the predictive performance of this study’s full HFO models with the results of 
models from the study in Chapter III. Considering either the entire patient cohort or even 
just the group of responder patients separately, there were no statistically significant 
differences or improvements in the magnitude (average test AUC) of prediction 
performance between the HFO rates analysis and the full HFO features analysis 
presented in this paper. Still, this study saw some improvement over Chapter III’s 
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results in the bootstrap p-values that were used to assess statistical certainty of these 
average test AUC. This is described below. 
To analyze how the full HFO features analysis could have improved the statistical 
certainty of better-than-chance AUC, we made a number of comparisons between the 
associated average p-values of the bootstrap test between the HFO rates analysis and 
the full HFO analysis presented here. Considering the entire cohort, median p values for 
the full HFO features analysis were qualitatively lower in the 15 minute feature window 
than for the rates analysis (Full HFO analysis: median bootstrap p value = 0.0025, HFO 
rate analysis: median bootstrap p value = 0.0190). We tested whether the full HFO 
features analysis could improve the statistical significance of patient-wise predictive 
performance when compared to previous HFO rates models. Applying a 1-sided sign 
rank test, bootstrap p-values for the full HFO analysis in the 15 minute feature window 
were nearly less than those for the HFO rates analysis, but this was not significant after 
correcting for multiple comparisons (Signed-rank right-tailed test: p=0.0235). 
Considering the performance of responder patients only (grouped independently by 
study), bootstrap p-values for the 15 minute feature window were again qualitatively 
lower than that of the rates analysis (Responders: Full HFO analysis: median bootstrap 
p-value = 0.00089, Responders: HFO rates analysis: median bootstrap p-value = 
0.00138), yet statistical comparisons of these values were also not significant (Rank-
sum right-tailed test: p=0.0652). Similar comparisons in other feature windows were not 
close to reaching statistical significance.  
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Important features: The choice of a machine learning tool like LASSO regression - 
rather than a black-box approach like deep learning - not only provides robust 
classification ability, but also yields an understanding of which features contribute the 
most to an observed trend, which potentially affords insight into underlying motivating 
mechanisms. Given the increased number of predictors in this study (270 in total) 
relative to the same number of seizures available as before, one of our primary 
concerns was model overfitting. To verify that the regularization of LASSO was 
functioning as intended, we analyzed on average how many variables were eliminated 
with LASSO to produce its final sparse models.  
Considering first all models that converged to a solution using HFO signal features 
(387 in total), the number of non-zero coefficients (variables) used in these models was 
on average significantly less than the total possible number of variables available 
(Number of non-zero coefficients in all convergent models: 30-minute: 6.72 / 270, 15-
minute: 6.96 / 270, 10-minute: 7.90 / 270) – this beneficially resulted in an average of 
97.3% of all possible predictors being eliminated with LASSO in these models. Further, 
the average number of variables in significant responder models was approximately one 
non-zero coefficient less (Responders: number of non-zero coefficients: 30-minute 
feature window: 6.08 / 270, 15-minute: 5.84 / 270, 10-minute: 6.71 / 270).  
One way to understand the importance of a given feature is to compare how 
frequently it was used across all models, that is, how often it was non-zero in models 
that converged. By this measure, the top 20 most important features to significant 
responder models are shown in Figure 13. As depicted in this figure, among the most 
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important features by frequency were those related to HFO rate (i.e. meta-features 
based on the number of detections – ‘nDets’ , or the inter-detection interval – ‘detIdi’). In 
terms of HFO signal features, meta-features based on frequency-domain measures like 
the amplitude at peak frequency in the power spectrum estimate (‘psePkAmp’) were 
among the most frequent. As before with the rates analysis, features in OUT channels 
were among the most important by their frequency, especially for the 30 minute feature 
window, where, with the exception of ‘Std-nDets-SOZ’ in 3rd place, the first eleven 
highest ranked features were computed from OUT channels. 
  
FIGURE 13: Relative frequency of features in significant responder models. The meta-features of 
HFO rate most important to discerning the preictal HFO response in responders are ranked in 
descending order (top to bottom) according to how often their respective model coefficients were 
non-zero for a given feature window. Overall, rate-based features such as the number of 
detections were seemingly most important; features in OUT channels were also significant, which 
is a novel finding that suggests channel location might not be vitally important in determining a 
preictal response in these responders.   
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We also assessed feature importance by directly comparing the magnitude of the 
coefficient values themselves. To make this possible, we first scaled ‘nDet’ features by 
the appropriate number of channels in SOZ or OUT groups by patient. Next, we used 
the median absolute deviation of all coefficients across the cohort (per feature window) 
to rescale individual coefficient values to unitless quantities. Shown in Figure 14, we 
compared these scaled values in significant responder models, and ranked their overall 
importance by feature window with their absolute value. As before with feature 
frequency, the number of HFO detections (nDets) was ranked highly, while signal-based 
FIGURE 14: Relative magnitude of important features in significant responder models. The magnitude of 
meta-features of HFOs most important to discerning the preictal HFO response in responders are 
ranked in descending order of their absolute value (top to bottom). One signal feature above all others 
was most important: the amplitude at peak frequency of the power spectrum estimate (psePkAmp). 
Rate-based meta-features were also important, as before with relative feature frequency. Overall, OUT- 
channel meta-features were significantly important again, especially dominating higher rankings of the 
30-minute feature window.   
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meta-features involving the amplitude at peak frequency of the power spectrum 
estimate of HFO waveforms (‘psePkAmp’) in particular were the highest-ranked signal 
feature in general. The importance of features in OUT channels was further reinforced, 
especially again for the 30 minute feature window, where OUT channel meta-features 
were top-ranked in the first five positions.  
Seizure advisory system results: The purpose of our seizure advisory system 
implementation was to translate the somewhat abstract conclusions of the average AUC 
results to a more meaningful and practical demonstration of their potential relevance to 
a physically realizable system. Similar to [69], we implemented the advisory system in 
two different ways so that it would give 1) an idea of possible predictive performance, 
versus 2) the actual predictive performance of the system when tested on held-out data. 
In Figure 15, a detailed example of the system’s output for patient UMHS-0028 for both 
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average and best trained models is visualized, while advisory output for average and 
best-trained models for all responder models is shown in Figure 16. 























































FIGURE 15: Example of seizure advisory system output. A detailed visualization of the seizure advisory 
system’s output is shown for patient UMHS-0028, a responder with significant average AUC in all three 
feature windows. Seizures are denoted with red diamonds, while preictal periods are visualized with red 
bars. Average model : The second plot row represents the warning system’s output for the average 
model of UMHS-0028 in the 15-minute feature window, which was created by optimizing the thresholds 
TH1 and TH2 in the seizure probability plot above this in the first row, where these probabilities were 
determined by the average model. The same plots are shown in the third and fourth rows, Best-trained 
model: where seizure probabilities were determined instead by the best trained model. In the third and 
fourth plot rows specifically, seizures trained on are represented by blue diamonds, while test seizures 
that were held-out are denoted with red diamonds. In this patient, the average model outperformed the 
best-trained model; both had similar sensitivity but the average model had higher specificity (fewer false 
positives).  
 



























































































































FIGURE 16: Advisory system output for select responder windows. Similar to Figure 15, visualized 
above are the advisory system’s results for several responder patients and various feature windows. 
Note that these patients include any responder whose average and best models converged to an 
optimum pair of threshold values; for some responders however, the thresholds did not converge and 
that is why such results are not presented above. Overall, in some patients the average model 
performed better, while in others the best-trained model performed just as well, though with higher 
specificity. There were very few instances, however, of the sensitivity of the best-trained models 
exceeding the sensitivity of average models. Again, for average models, red diamonds represent only 
seizures while for best-trained models, blue diamonds represent training seizures, while red diamonds 
represent test seizures that were held out in training.   
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In Table 4 below, we compare the advisory performance of average and best-
trained models for significant responder models. For average responder models, the 
median percentage of time spent in high warning ranged from 13.6% (15 minute 
window) to 17.2% (10 minute feature window). The median performance of the best 
trained responder models was even better considering this metric – ranging from 3.3% 
(30min) - 5.8% (15 min). Next, considering the percentage of seizures correctly 
identified for each warning level, the median values of average models were slightly 
higher (qualitatively) than the best trained responder models; these values ranged from 
72.7% (10min.) to 88.9% (30min) (Best-trained models: 10min.: 56.0% 30min.: 80%). 
Considering seizures identified in low warning (which are essentially false negatives), 
the average models performed better than the best trained models, with 0% false 
negatives for all feature windows. Finally, we consider the average warning time in high 
level before seizure onset occurs (i.e. its prediction horizon). In average responder 
Significant responder models: median performance
Feature window: 30min 15min 10min
Warning level: Average model:





















High 13.7% 88.9% 15.2 13.6% 87.3% 11.0 17.2% 72.7% 7.8
Med 25.5% 11.1% - 25.0% 10.6% - 30.1% 10.0% -
Low 55.3% 0.0% - 62.1% 0.0% - 52.2% 0.0% -
Best trained model:





















High 3.3% 80.0% 10.6 5.8% 75.0% 8.6 5.0% 56.3% 3.3
Med 18.9% 20.0% - 28.0% 20.0% - 21.4% 16.7% -
Low 77.8% 0.0% - 58.3% 5.0% - 75.7% 10.6% -
TABLE 4: Responder advisory performance comparisons. Median advisory performance for average 
and best-trained models in all feature windows is reported below for the three performance metrics 
compared: the percentage of time spent in a level, the percentage of seizures correctly identified per 
level, and the average prediction horizon in high warning. In general, the sensitivity of average models 
was higher than best-trained models, while this was reversed for prediction specificity. Average 
prediction horizons were significantly longer in average models. (P< 0.05, 30 and 10 min. features 
windows). 
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models, this ranged from 7.8 minutes (10minute feature window), to 15.2 minutes (30 
minute feature window). For the best trained models, these values had a range of 3.3 to 
10.6 minutes (10, 30 minute feature windows); these values for average models were 
significantly longer in duration than those for the best trained models (Rank-sum test: 30 
min: P <  0.05, 10 min: P < 0.05).  
Discussion 
We analyzed the temporal characteristics of HFO signal features to evaluate their 
potential contribution to enhanced seizure prediction performance relative to that of 
HFO rates alone. In general, the data and results presented in this study offer further 
supporting evidence that HFOs can act as temporal biomarkers of epilepsy.  
Comparing HFO rates with features: The number of responder patients increased 
by three individuals in this study to a total of 13. Despite these additional responders, 
however, the use of HFO signal features did not result in significant systematic cohort-
wide improvements in seizure prediction performance, as reflected in the average test 
AUC metric. Yet, there were qualitative indications - for the entire patient population and 
separately for responder patients - that the certainty or confidence of this test 
performance against random-chance prediction was increased by HFO signal features. 
While narrowly missing statistical significance, comparisons of this model certainty with 
that of HFO rates nevertheless demonstrated that HFO signal features have the 
potential to improve HFO-based seizure prediction. For certain responder individuals 
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like patient UMHS-0028, the increases in prediction performance resulting from the use 
of HFO signal features were considerable.  
Despite the limitations of this study's short-term intracranial monitoring data, the 
predictive performance of our HFO-based classification algorithm for certain patient 
subsets was reasonably within the range of several notable seizure-prediction studies 
that each used the more ideal chronic Neurovista datasets. The top-ranked 
classification algorithm in the Kaggle seizure prediction contest of 2016, for instance, 
achieved an overall AUC of 0.81, which reduced to 0.76 when tested with held-out data 
[64]. Prediction studies conducted since the 2016 competition have achieved similar 
performance, including one where the range of average AUC by patient was 0.69 - 0.90 
[65]. Given the differences in the data and methods used, it is difficult to directly 
compare our results with these studies. Still, there were five responder patients with 
average test AUC values over 0.80 - which suggests that HFO-based seizure prediction 
performs similarly.  
As in our rates analysis of Chapter III, we also analyzed which HFO features were 
the most important to identifying preictal periods. In responder models, the most 
common features tended to be rate-based, while a varied mix of linear and nonlinear 
signal features in both time and frequency domains were also common. Ranked by the 
absolute value of their magnitude, the features that contributed significantly to 
identifying the preictal state in responders were also rate-based, but one signal feature - 
the amplitude at peak frequency of the power spectrum estimate (abbreviated 
‘psePkAmp’) - emerged as top-ranked. As in our rates analysis of Chapter III, meta-
 
  86 
features computed across OUT channels were highly ranked, which again suggests that 
HFOs outside the SOZ might be linked to preictal states – this has limited but intriguing 
support in the literature [121].  
With our implementation of the seizure advisory system, we put the positive 
predictive performance of responder models into the context of ‘pseudo-prospective’ 
seizure prediction. For average and best-trained responder models, the percentage of 
time spent in high warning was within the performance reported by the one true 
prospective study (which, for their responder patients, ranged from 30% - 3%) [66]. Next 
considering the percentage of seizures correctly identified for each warning level, all 
values reported for average and best trained responder models were within range of the 
same values reported in a recent pseudo-prospective study using the NeuroVista data 
[69]. In general description, the average models had better sensitivity, and were better 
at identifying seizures in high warning when compared to the best trained models. 
Conversely, the best trained models tended to be more sensitive, with higher 
percentages of time spent in low warning and less false positives. These same 
relationships between average and best trained models were also similarly reflected in 
the performance of the two evaluation methods detailed in [69] – the performance of 
their advisory system was more sensitive when trained with all data, and it was more 
specific when the probabilities were evaluated pseudo-prospectively (or, without 
knowledge of some seizures, as was emulated in our best- trained method).  
These encouraging results were achieved with more limited data. In contrast to the 
study discussed above [69], however, it is important to note here that our advisory 
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system cannot truly be considered pseudo-prospective, as the predictive models used 
to generate the probability of a seizure in time were those that had been either cross-
validated over the entire dataset (as in the average models) or those that were trained 
on seizures that could have originated from any particular time within the dataset; and 
thus the division of data for another held-out test set was unrealistic given that the 
number of seizure observations was already very small. As such, the results of our 
advisory system likely represent a 'best possible' outcome (average models) or a more 
realistic outcome (best trained models) because training data (along with test data) 
generated the system's output - and the corresponding average training AUC from 
these data was often extremely high (near 0.90 or above) for many patients (data not 
shown).  
Still, this approach of using the full extent of available data in time was recently 
used in another seizure prediction study based upon the chronic NeuroVista data [69]. 
This 'best-possible' method was presented as a way to discern an upper bound on 
predictive performance by patient - which is essentially a model's predictive potential. 
This bound was then compared with the more realistic performance of a true pseudo-
prospective prediction algorithm, which allowed the authors to estimate potential gains 
in predictive performance that future work could mine with the aid of better methods or 
more ideal datasets. Here, we emulate these methods, because we have limited data, 
but still must show the value of HFOs in seizure prediction. Given that the requisite 
high-density iEEG dataset of sufficient duration does not currently exist, the results of 
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our seizure advisory system thus stand as a proof-of-concept only and are not intended 
as validated evidence of actual pseudo-prospective seizure prediction performance.  
Another concern with the methods of this study could be that of overfitting, which 
can result when too many variables are used to characterize too few observations. 
Though the number of predictors in this study increased to a total of 270, we attempted 
to account for this increased number of variables by the use of LASSO methods: the 
resulting reduction in variables was evident considering that only an average of roughly 
7 out of 270 variables were used in most predictive models. Future work using HFO 
signal features could better account for the reduced number of seizure observations 
relative to high numbers of predictors and interictal baseline data by using more 
advanced forms of dimensionality reduction, or even by using unsupervised prediction 
approaches that characterize excursions in the data without pre-defined labels of what 
‘is’ or ‘is not’ a seizure.  
Conclusion: The findings of this paper add further support to the notion that HFOs 
are temporal biomarkers of seizure onset in refractory epilepsy. These results also 
indicate that the use of many signal-based features might not justify the computational 
cost of including them in future device architectures, as HFO-based seizure prediction 
using only HFO rates performed similarly. Overall, these findings are powerful evidence 
for the development of chronic datasets that support high-density intracranial EEG 
recordings, which will enable future work on HFO-based seizure prediction.   
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Chapter V: Discussion and Conclusion 
This thesis represents a significant contribution to our understanding of high-
frequency oscillations in refractory epilepsy. Enabled by the use of a large clinical 
cohort, as well as methodological advances in peri-ictal HFO processing, each of the 
studies in the preceding chapters successively built and developed a framework of 
evidence to support the novel idea that high-frequency oscillations can act as temporal 
biomarkers of epilepsy and seizure onset. Overall, the strength of this temporal 
association with preictal periods was variable among patients, a finding likely reflective 
of the diverse etiologies of clinical refractory epilepsy. In certain ‘responder’ patient 
subsets, however, this preictal HFO signal was clearly identifiable and consistent. In a 
first-of-its-kind analysis, this thesis also confirmed that it is possible to use the temporal 
properties of HFOs in seizure prediction; again for certain ‘responder’ patients, the 
performance of HFO seizure prediction algorithms was robust and significant.  
This thesis also represents methodological advances related to HFOs and seizure 
prediction. Throughout the three studies presented, a number of novel approaches were 
introduced to identify, process, and analyze HFOs near seizures. First, HFOs that 
resembled muscle activity occurring near the surface of the scalp were redacted as 
artifacts; this increased HFO specificity, especially near or during seizures, given that 
ictal muscle contractions could significantly impact automated detection. These three 
studies are the first to use this technique to improve HFO detection near seizures. 
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Second, the problem of calculating a baseline threshold for HFO detection near 
seizures was addressed by modifying how data were fed to the automated detector, 
which prevented high-amplitude seizure activity from arbitrarily influencing this threshold 
for detection. Lastly, in order to analyze changes in HFOs with sufficient resolution in 
time, HFO characteristics (i.e. their rate or signal features) were transformed into novel 
continuous measures, which also made these quantities more useful in the context of 
seizure prediction. In terms of seizure prediction, specific limitations in iEEG monitoring 
data related to its duration or temporal volatility were addressed by randomly 
partitioning training and testing observations in time, instead of in chronological order. 
While the use of random data sampling is certainly not novel, its intended purpose for 
use in seizure prediction with limited hospital monitoring data can be considered so.  
In general, the use of these methods would not have been possible without first the 
creation of a flexible framework of computer code that could accommodate the messy 
clinical reality of a large epilepsy database. The upfront investment in time and effort for 
the creation of this framework was significant, but this was necessary in order to 
overcome the technical challenges of analyzing millions of very short events occurring 
across 190 days of high-resolution intracranial EEG data, which were recorded from 30 
different patients in an epilepsy database with over 50 terabytes of total data.  
Overall the central goal of this thesis was to evaluate temporal changes in HFOs to 
see whether they could differentiate the preictal brain state from other interictal times.  
The study in Chapter II first assessed whether this preictal effect was at all present in 
individuals, and if so, how prevalent it was across a large clinical cohort. First at an 
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individual level, a potential stereotypical response was evaluated by comparing preictal 
and interictal data trends in aggregate. The extent and prevalence of this preictal effect 
across the entire cohort was then determined with population-level inference. There 
were no population-wide differences in preictal and interictal HFO rates when averaged 
over long periods of time. Using a novel continuous transform of HFO rates, however, 
we identified significant population-wide linearly increasing trends in preictal HFO rates 
occurring within epileptic channels that were absent during interictal times. Examining 
the population distribution of these temporal trends, we further identified a ‘responder’ 
subset of 10 patients, each with significantly increased preictal HFO trends relative to 
others in the cohort.   
These findings are supported by earlier preliminary findings as documented in [56] 
and [55]. Other studies that investigated high-frequency activity before seizures also 
found evidence of stereotyped preictal changes for certain individuals [74], [99]– which 
lends support to our identification and separation of the ‘responder’ patient subset. 
In addition to the limitations mentioned in the discussion section of Chapter II, the 
manner in which data were aggregated for this study’s main analysis – which was 
grouped first by channel group, then by preictal or interictal segments, then at the 
population level – bears some additional consideration. In statistics, repeated 
measurements taken from the same statistical subject – either at different points in time  
or for multiple factors or variables –  are considered dependent. Thus, in order to apply 
population-level statistical inference to these measurements, this dependence must in 
some way be accounted for. Ideally, the manner in which these measurements covary 
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is known. Considering the nature of the HFO data in this study – which originated from 
many different patients with different epileptic foci, pathologies, sleep habits, medication 
protocols, electrode types and configurations, and possibly different seizure types – it 
was apparent from the variability of the findings from patient to patient and even 
between different seizures of the same individual that it would be impossible to fully 
specify this covariance for all patients.  
Still, we utilized two small adjustments in our analysis to ameliorate the influence of 
these unknown covariates. First, we assumed that channels from the same group 
(either SOZ or OUT channels) would covary similarly to one another in order to reduce 
the covariance between individual channels. Whenever possible, we performed paired 
statistical tests like the signed-rank test – which are better suited to repeated measures 
designs [122]. These pairwise comparisons within patients were implemented to reduce 
covariance between individuals when assessing population-level significance. Though 
we did not attempt it here or in the other studies of this thesis, future work comparing 
population-level HFO data in aggregate would benefit from fully specifying the 
covariance between all data observations – though this would potentially require much 
more data than might be available with hospital monitoring sessions. Another potentially 
more feasible approach is to use a statistical method – such as the method of 
generalized estimating equations [123] –  that robustly adjusts estimated data by its 
covariance, even when the structure of this covariance is unknown.  
The studies presented in the third and fourth chapters extend the methods and 
findings of the first study in significant ways. While the first study was centered on 
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population-level comparisons of HFO trends for its analysis, these studies focus on 
patient-specific analyses in order to demonstrate their relevance to seizure prediction. 
To further facilitate their intended context in seizure prediction, they compare preictal 
and interictal data segments individually, rather than in aggregate, as was used in the 
first study.  
The analysis of the third chapter characterized temporal changes in continuous 
HFO rates in a similar manner as the first study. Instead of comparing these values 
using population inference, however, the study in Chapter III used them to create 
logistic classification models that could be used in seizure prediction. The overall 
process of training these predictive models and then testing them with new held-out 
data was cross-validated over ten randomized runs, which allowed for a more realistic 
and consistent assessment of their ability to differentiate preictal and interictal data. We 
used a minimal statistical benchmark to differentiate patient models with better-than-
chance predictive ability; applying this criteria to the average test AUC over all patients 
resulted in the identification of 10/27 ‘responder’ patients, who each had a significant 
result in at least one of the feature windows.  
The methodology of the third study in Chapter IV expanded to incorporate additional 
information about HFO signal features, which we hypothesized could improve seizure 
prediction, based on the usefulness of HFO features in other studies. Other than the 
use of these additional features, the overall methodology of the second and third studies 
was the same. This allowed us to directly test our hypothesis that the use of HFO signal 
features might aid prediction performance. The results from this study identified a total 
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of 13 responder patients – a gain of three responders over the prior study. Despite 
these additional responders, there was no statistical evidence that the use of expanded 
HFO features resulted in higher average test AUC, though the statistical performance of 
these models as reflected in their average bootstrap p values was improved for some 
comparisons. Overall however, this is actually a positive result because it suggests that 
using only HFO rate – which is easier to compute – might be sufficient for accurate 
seizure prediction; this would be especially useful for the translation of our algorithm into 
a physical device.  
There is no direct evidence in the literature to support the findings of the second 
and third papers, because to our knowledge there are no studies that use HFOs in 
seizure prediction. Considering both studies together however, the average test AUC of 
responder patients was well within the range of results reported in many other prediction 
studies in the literature, [63]-[65] and many of these studies had the advantage of the 
much longer Neurovista dataset, while our studies did not.  
Specifically considering the seizure advisory system of the third paper, overall, the 
performance of the average model in responders was quite high, and was within range 
of other prediction studies using the advisory system method [66], [69].  The 
performance of our advisory system for more realistic models that were not trained on 
all seizures was comparatively more variable and reduced. Still, some patients achieved 
excellent results despite their models not being trained on all seizures. Considered 
altogether, the reasonable performance of the seizure advisory system for some 
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patients further demonstrates the potential that HFOs could have in seizure prediction – 
provided that the right data is available for such continued work.  
The studies presented in the second and third chapters do have some inherent 
limitations. The primary limitation for both is the required use of relatively short datasets 
that are characterized by many variable and non-stationary exogenous factors. These 
data are in no way representative of the normal ambulatory setting that a seizure 
prediction device would eventually operate in [12]. As such, the number of seizures 
captured per patient is generally far less than would be minimally required for patient-
specific and seizure-specific prediction. This results in a significant imbalance between 
the number of preictal and interictal observations – and this imbalance is made worse 
when data are evaluated continuously through time, as is the case with these studies. 
This imbalance can result in overtrained models that perfectly identify certain seizures 
while effectively ignoring others. In both studies, however, we attempted to address 
potential overfitting by minimizing cross-validation error during model training.  
The limited number of seizures recorded per patient is also problematic given the 
large number of predictive features used in both studies, especially in the third. This 
imbalance of (many) predictors and (few) observations can also result in model 
overfitting. This consideration was a primary reason for our use of LASSO regression in 
both studies; given that approximately 97% of variables were eliminated with LASSO in 
convergent models of the full HFO analysis of Chapter IV, the imbalance of variables to 
observations in this case was significantly reduced. Even with this reduction, however, 
the possibility for model overfitting existed – which is why only testing performance (i.e. 
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model performance on held-out data) was reported for both studies, which was also 
averaged across all ten randomized cross-validation runs to better inform the 
consistency of this performance in patients.  
In both studies, the last major caveat to consider is also derived from limited 
number of recorded seizures per patient. The AUC performance metric has been a 
standard tool used by many noteworthy prediction studies [63]–[65], [68] to describe the 
overall predictive performance of their seizure prediction models. While the use of this 
single value as a performance metric has many advantages, the imbalance of preictal 
and interictal data can also complicate the interpretation of associated AUC by 
overstating the specificity of a model [62], which, for these studies, is how often interictal 
segments were correctly identified. Additional limitations to our use of AUC in these 
studies also occur because the ratio of interictal to preictal data was not constant across 
patients and feature windows; this was a design choice that was necessary because of 
limited data in many patients. Finally, given the eventual clinical implications of online 
seizure prediction or forecasting algorithms to the patients themselves, it is unlikely that 
an abstract performance metric like AUC would hold any meaning to patients or 
clinicians alike when trying to optimize an algorithm’s efficacy. This is in part the reason 
for concluding the third and final study with the seizure advisory demonstration, for if 
seizure prediction and forecasting algorithms and their results are not interpretable, 
there is likely little chance they will be useful to patients and clinicians – which could 
further stunt their widespread adoption. 
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The studies presented in this thesis form a foundation of preliminary evidence that 
support HFOs as a temporal biomarker in epilepsy. Given the limited data that were 
required for this work, future studies could validate these principal findings in different 
high-density datasets recorded from many clinically diverse patients. Ideally, this 
validation would also systematically account for the significant variability of data 
between different recorded channels, patients, and even between seizures. Using a 
robust statistical tool like the generalized estimating equations in this regard could better 
inform the statistical conclusions of population-level HFO analyses (such as those that 
were conducted in the first study). This could in turn identify certain clinical factors that 
might significantly predispose an individual to being a preictal HFO ‘responder’.  
In the field of seizure prediction, future studies using HFOs in this manner will likely 
require high-density intracranial EEG datasets that are ambulatory and much longer, 
containing many more seizures. If such data existed, future work could rigorously 
investigate HFO-based seizure prediction in the context of patient-specific and even 
seizure-specific algorithms. Such work could use sophisticated non-linear machine 
learning classifiers to finally tease out differences in preictal HFOs by seizure type. Also 
possible in this future work could be the use of unsupervised machine learning 
techniques which have also been used in health diagnostic studies [124], [125]; these 
methods are not as biased as supervised methods such as logistic regression because 
they abandon notions of preictal and interictal periods and instead characterize outliers 
in the data regardless of what or when such excursions are or occur.  
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Conclusion 
The work of this thesis has identified and developed a novel pre-seizure biomarker 
that has significant clinical potential for patients with drug-resistant epilepsy. This work 
confirms that high-frequency oscillations are temporal biomarkers of seizure onset, and 
shows further that HFOs can be used in seizure prediction, especially for certain 
individuals. While there are likely many challenges in the winding road toward seizure 
freedom for many, it is hoped that the work of this thesis eventually contributes in some 
small way to the gathering global effort to reduce and eliminate the influence of seizures 
on the everyday lives of those suffering from epilepsy.  
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